American University in Cairo

AUC Knowledge Fountain
Theses and Dissertations

Student Research

2-1-2016

Regulatory networks in non-small cell lung cancer: Connecting
differentially expressed genes, miRNAs, and incRNAs
Jasmine Omran

Follow this and additional works at: https://fount.aucegypt.edu/etds

Recommended Citation

APA Citation
Omran, J. (2016).Regulatory networks in non-small cell lung cancer: Connecting differentially expressed
genes, miRNAs, and incRNAs [Master's Thesis, the American University in Cairo]. AUC Knowledge
Fountain.
https://fount.aucegypt.edu/etds/1379

MLA Citation
Omran, Jasmine. Regulatory networks in non-small cell lung cancer: Connecting differentially expressed
genes, miRNAs, and incRNAs. 2016. American University in Cairo, Master's Thesis. AUC Knowledge
Fountain.
https://fount.aucegypt.edu/etds/1379

This Master's Thesis is brought to you for free and open access by the Student Research at AUC Knowledge
Fountain. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of AUC
Knowledge Fountain. For more information, please contact thesisadmin@aucegypt.edu.

School of Sciences and Engineering

Regulatory Networks in Non-Small Cell
Lung Cancer: Connecting Differentially
Expressed Genes, miRNAs, and lncRNAs
A Thesis Submitted to the:
The Biotechnology Graduate Program
In partial fulfillment of the requirements for
The degree of Master of Science in Biotechnology

By: Jasmine Kamal Omran
Bachelor of Science in Human Biology, University of California San Diego
Under the supervision of Dr. Hassan Azzazy
Professor, Department of Chemistry, The American University in Cairo
December/2016

The American University in Cairo
School of Science and Engineering
Regulatory Networks in Non- Small Cell Lung Cancer: Connecting Differentially
Expressed Genes, miRNAs, and lncRNAs
A Thesis Submitted by: Jasmine Kamal Omran
To the Biotechnology Graduate Program
December 2016
In partial fulfillment of the requirements for the degree of
Master of Science in Biotechnology
Has been approved by:

Thesis Committee Supervisor/Chair ________________________________________________
Affiliation_____________________________________________________________________
Thesis Committee Supervisor _____________________________________________________
Affiliation_____________________________________________________________________
Thesis Committee Reader/Examiner ________________________________________________
Affiliation_____________________________________________________________________
Thesis Committee Reader/Examiner ________________________________________________
Affiliation_____________________________________________________________________

_________________

______________

________________

Dept. Chair/Director

Date

Dean

ii

________________
Date

DEDICATION

I dedicate this thesis to my mother and father. My mother provides me with unconditional love,
support, and motivation. She is my queen. She is the power behind the throne of the person I am
today. And my father taught me early on that being compassionate was not enough to achieve my
dream of becoming a doctor; he taught me that it requires diligence and perseverance. He
instilled in me the desire to contribute to society. And despite my losses I still view life with
enchanted optimism.

iii

ACKNOWLEDGEMENTS

First and foremost, I would like to thank my thesis advisor, Dr. Hassan Azzazy for all of his
support. I would like to thank him as he helped me grow not only as a student but also as a
scientist and a teacher. He continues to inspire me with his devotion to students and immense
scientific knowledge. He is a role model for hard work and scientific innovations. Next, I would
like to thank all my professors in the AUC Biotechnology program for contributing to the honing
of my scientific knowledge. Also, I would like to thank Ahmed Elhosseiny for his support,
bioinformatics help, and late hours. He is an icon of hard work and resilience. Also, I would like
to extend many thanks to Marwa Zahra as she is supportive and provided her time, guidance,
and intelligence. Last but not least, I would like to extend my gratitude to my mother and my
friends for believing in me and for their continuous support.

iv

ABSTRACT

The American University in Cairo

Regulatory Networks in Non-Small Cell Lung Cancer: Connecting
Differentially Expressed Genes, miRNAs, and lncRNAs
By: Jasmine Omran
Under the Supervision of: Dr. Hassan Azzazy
Non-small cell lung cancer (NSCLC) is the most prevalent class of lung cancer and the most
common cancer worldwide. NSCLC accounts for 85% of total lung cancer cases and leads to the
most cancer-related deaths worldwide. Long non-coding RNAs (lncRNAs) and micro RNAs
(miRNAs) are gene regulatory elements that play crucial roles in cancer biology such as cancer
cell growth and metastasis. Understanding the gene regulatory elements that influence cancer
biology is critical for diagnostic and therapeutic purposes. A systems approach can help simulate
interactions between these elements. In this study 110 microarray samples from NSCLC patients
were analyzed by computational methods to identify differentially expressed genes in two tissue
types: NSCLC and normal lung tissue. Identified differentially expressed genes were
functionally clustered and annotated with their miRNA and lncRNA targets using miRTarBase
and starBase, respectively. Regulatory networks were created to suggest an interplay between
these miRNAs, lncRNAs, and differentially expressed genes. This approach led to the
identification of 108 differentially expressed genes. Innumerable miRNAs target the
differentially expressed genes but 66 miRNAs were identified by literature mining and strong
evidence validation methods to identify miRNA and differentially expressed gene targets. The
filtered miRNAs were also paired with seven of the most common NSCLC-associated lncRNAs.
Based on the findings of this computational study and other studies in literature, connections of
differentially expressed genes, miRNAs, and lncRNAs were suggested. TGFBR3 and HHIP,
tumor suppressor genes, and CAV1, an oncogene, were functionally related to carcinogenesis
and cancer cell metastasis, respectively and were related to cell signaling and extracellular matrix
genes. This study suggests that MALAT1, PVT1, and GAS5 are lncRNAs that regulate gene
expression via miRNA targeting. Since miRNAs, and lncRNAs are instrumental gene regulatory
factors in determining NSCLC diagnosis and prognosis, these regulatory pathways can lead to
novel approaches in cancer therapy. Therefore, these networks propose mechanisms of actions to
further study miRNAs and lncRNAs suggesting a crosstalk between miRNAs, lncRNAs, and
differentially expressed genes.
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CHAPTER 1: Introduction
1.1. NSCLC

1.1.1. Epidemiology
Lung cancer encompasses two main categories: small cell lung cancer (SCLC) and nonsmall cell lung cancer (NSCLC). NSCLC is the more prevalent of the lung cancers responsible
for 85% of those diagnosed with lung cancer. NSCLC encompass adenocarcinoma, squamous
cell carcinoma, and large cell carcinoma. Lung cancer is the prevailing cause of cancer-related
deaths worldwide for both males and females and is more common in the older generation (65
years or older). More specifically, lung cancer is the most common cause of cancer relateddeaths in males while it is the second most common cause of cancer related-deaths in females. In
both sexes, 19% of all cancer deaths are attributed to lung cancer alone totaling to 1.6 million
deaths (CDC). According to the American Cancer Society, 1 out of 4 cancer-related deaths are
due to lung cancer. More deaths result from lung cancer every year than of colon, breast, and
prostate combined (American Cancer Society).
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Figure 1. Sub-groups of Lung Cancer (Lilly Oncology).
Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are two dominant
classifications within lung cancer. NSCLC accounts for 85% of lung cancer diagnoses and
encompasses adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Figure was
reproduced with permission from reference 30; see appendix.

Figure 2. Most Common Cancers Worldwide in 2012 (CDC).
In both males and females, lung cancer is the most common classified cancer globally (CDC).
Figure was reproduced with permission from reference 7; see appendix.
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Figure 3. Most Common Causes of Cancer Death Worldwide in 2012 (CDC).
In both females and males, 19% of all cancer-related deaths are due to lung cancer accounting
for 1.6 million deaths (CDC). Figure was reproduced with permission from reference 7; see
appendix.
1.1.2. Statistics
According to the American Cancer Society, 158,080 Americans are supposed to die in
2016 which will be responsible for 27% of all cancer deaths. Also, as indicated by the American
Lung Association and the American Cancer Society, an expected 224,390 Americans are
expected to be diagnosed with lung cancer in 2016 accounting for 14% of all cancer diagnoses.
Despite these statistics, the incidence rate for both men and women has been declining. One in
14 men and one in 17 women are likely to develop lung cancer during their lifetime (American
Cancer Society).

1.1.3. NSCLC in Egypt
Lung cancer accounts for 5-7% of cancers in Egypt (National Cancer Registry Program).
The incidence rate in Egypt is expected to drastically increase by a 3-time fold in both males and
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females until the year 2050. The expected number of cases are expected to reach over 140,000
and 160,000 for women and men, respectively until the year 2050 according to the National
Cancer Registry Program of Egypt (NCRP) (Ibrahim, Khaled et al. 2014).

Figure 4. Incidence rates of the most frequently observed cancers in Egypt.
In Egypt, lung cancer is ranked third and fourth amongst males and fifth amongst both genders
(NCRP) (Ibrahim, Khaled et al. 2014). Figure was reproduced with permission from reference
21; see appendix.
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Figure 5. Estimated number of cancer cases in Egypt 2013-2015.
According to the National Cancer Registry Program (NCRP) in Egypt, the incidence rate is
expected to drastically increase by 3-time fold in both males and females until the year 2050
genders. The expected number of cases are expected to reach over 140,000 and 160,000 for
women and men, respectively until the year 2050 (Ibrahim, Khaled et al. 2014). Figure was
reproduced with permission from reference 21; see appendix.

1.1.4. Risks and Protective Factors of NSCLC
Some of the risks that lead to NSCLC are cigarette smoke, second hand smoking, alcohol
consumption, and occupational exposure to carcinogens such as radon and asbestos (American
Cancer Society). Long-term air pollution exposure, previous radiation therapy to the lungs, and
family history of lung cancer are irreversible risk factors (American Cancer Society). The
heredity inheritance of the TP53 gene and other chromosome markers may also lead to lung
cancer (American Cancer Society). Any combination of these risk factors increases the
likelihood of lung cancer. Some protective factors of lung cancer include exercise, specifically
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leisure-time physical activity and fruits and vegetables that are rich in antioxidants, even among
heavy smokers (Molina, Yang, Cassivi, Schild, & Adjei, 2008).

1.1.5. Smoking and NSCLC
NSCLC is more common amongst former smokers (60%) than current smokers (25%)
(American Lung Association). Male and female smokers are 23 and 13 times, respectively, more
probably to develop lung cancer than those who never smoked (American Lung Association).
Nonsmokers have a 20 to 30% chance of developing lung cancer if disclosed to second-hand
smoke (American Lung Association). Smoking leads to 90% and 80% of male and female lung
cancer related-deaths, respectively (American Lung Association).
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Figure 6. Smoking, a cause of cancer-related deaths.
Smoking is the dominant element of cancer related deaths followed by other pulmonary diseases
and heart disease (National Cancer Institute). Figure was reproduced with permission from
reference 38; see appendix.
1.1.6. Types of NSCLC
Adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are three primary
divisions in NSCLC. Adenocarcinoma effects the outer area of lung and accounts for 40% of
lung cancers; it is slower to spread and is considered the most common form of cancer in
smokers or former smokers but it is also the most popular form of cancer in nonsmokers.
Squamous cell carcinoma, flat cells that line the airways, effects the center of the lung and
bronchi and accounts for 25-30% of lung cancers and is connected to a smoking history. Large
cell (undifferentiated) carcinoma effects any part of the lung and accounts for 10-15% of lung
cancers. Large cell carcinoma grows and spreads fast (American Cancer Society).
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1.1.7. NSCLC Signs and Symptoms
A worsening cough, a new onset of wheezing, coughing up blood or rust-colored phlegm,
shortness of breath, chest pain, weight loss, loss of appetite, recurring respiratory conditions are
among the most common symptoms that appear with lung cancer patients (American Cancer
Society). Usually lung cancer is pronounced at a later disease phase or when the disease spreads
to distant body parts. As the lung malignancy metastasizes to the brain or spinal cord, bone pain
and nervous system changes may occur. If the lung cancer spreads to the liver this may result in
jaundice. Symptoms increase and appear as the cancer progresses and proliferates. Some cancers
may even lead to syndromes like: Horner syndrome, superior vena cava syndrome, and
paraneoplastic syndromes. Lung cancer screening is recommended for patients that are 55-74
years old, in fairly good health condition, and are currently smoking or formerly smoked in the
past 15 years (American Cancer Society). Lung cancer screening is also recommended for
patients with a “30 pack-year smoking history” meaning the patient smoked one cigarette pack
per day for 30 years (American Cancer Society).

1.1.8. NSCLC Diagnosis and Treatments
The current diagnostic procedure includes a medical history and physical exam, chest xray, chest CT scan with infusion or contrast material, and biopsy (American Cancer Society).
Lung cancer is diagnosed microscopically by observing a collection of lung cells (American
Cancer Society). Current treatments include surgery, radiation therapy, combination
chemotherapy such as Cisplatin and Paclitaxel (Taxol), targeted therapy such as Bevacizumab
and (Avastin) and Ramucirumab (Cyramza), and immunotherapy like Nivolumab (Opdivo)
(American Cancer Society). Treatment of NSCLC depends on the stage of the cancer (American
Cancer Society).
8

1.1.9. NSCLC Stages
The stage of the disease is according to the size of the tumor and progression of the
spreading of the cancer. Stage 0 is considered the non-invasive stage and the cancer cells are
found in the airway lining and have not spread any further. Stage 1A is the beginning of invasive
stages; the tumor size is ≤3 cm and the tumor has grown through the airway lining into deep lung
tissue. Stage 1B, the abnormal mass size is ≥3cm and the tumor has reached the primary airway.
Stage 2A, the tumor is ≤3 cm and the tumor has proliferated to nearby lymph glands on the same
side of the chest. Two types of stage 2B progression are present. Stage 2B1, the tumor is ≥5 cm
and the tumor has advanced to the lymph nodes. Stage 2B2, the tumor is ≥7 cm and the tumor
has not penetrated the lymphatic structure or distant structures. Stage 3A, the abnormal mass
varies in size and the cancer spreads to the lymph nodes on the same side of the lung tumor and
to nearby structures such as the chest wall and other parts of the thoracic cavity. Stage 3B, the
tumor can be any size and the cancer spreads to the lymph glands above the chest or to the other
side of the chest and nearby structures. Stage 4, the tumor can be any size and the malignancy
spreads to other body parts such as the brain, bone, liver, and adrenal glands (American Cancer
Society).
1.2. Gene Regulation

1.2.1. miRNAs
miRNAs are 22 nucleotides in length; these small non-coding pieces of RNA were
overlooked until their discovery in 1993. miRNAs play different roles in various cancers
including post transcriptional gene regulation, cell-to-cell communication, and cell cycle
regulation. miRNAs are known gene regulatory factors that can function as tumor suppressors
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and oncogenes. The abnormal miRNA expression levels signify an anomalous state and can be
used to target cancer regulatory pathways and provide insight into disease progression. This can
lead to the uncovering of original biomarkers and curative breakthroughs. Hence, the study of
miRNAs and the fluctuation of miRNA levels is a growing field for disease progression,
prognosis, diagnosis, and therapy.
1.2.1a. miRNA Biogenesis
Diseased states of miRNA targets may result from alterations in the processing of
miRNAs; hence, it is important to understand the biogenesis of miRNAs. miRNA biogenesis
begins in the nucleus where primary miRNAs (pri-miRNA) are processed by Drosha into premiRNAs before leaving the nucleus. In the nucleus, Drosha, an RNase III enzyme removes the
tails of the pri-miRNA, consisting of 1- 4 kilobases, which leads to the formation of a stem loop
called precursor miRNA (Pre-miRNA) to construct the 22 nucleotide non-coding sequence
(Bartel 2004). Pre-miRNAs are transported from the nucleus via Exportin 5. Once out of the
nucleus, the pre-miRNA is further prepared by Dicer in the cytoplasm. Dicer removes the stem
loop from the pre-miRNA producing a mature miRNA. The mature miRNA can be primed into
the Argonaute protein in the RNA-induced Silencing Complex also known as RISC (Bartel
2004). This RISC complex in turn degrades mRNA and or represses gene expression. This
further proves the ability of miRNAs to regulate gene expression post transcription.
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Figure 7. miRNA Biogenesis overview.
Primary miRNA (pri-miRNA) transcribed by pol II or pol III must be processed by Drosha
before it is exported from the nucleus. After processing takes place pri-miRNA becomes
Precursor miRNA (Pre-miRNA). Pre-miRNA is transported from the cytoplasm to nucleus via
Exportin 5 and is further refined by Dicer to produce a mature micro RNA (miRNA). Mature
miRNA can be armed into the Argonaute protein containing RNA-induced silencing complex
(RISC). This RISC complex consecutively degrades mRNA and represses gene expression
(Rothschild, 2013). Figure was reproduced with permission from reference 42; see appendix.
1.2.1b. miRNA Functions
miRNAs have various functions including post-transcriptional gene regulation, cell-tocell communication, and cell cycle regulation all of which are important to understand disease
progression. miRNAs create related cell networks and loop mechanisms to regulate many target
cells simultaneously (Gurtan and Sharp 2013). This proves the ability of miRNAs to reach
multiple targets which further confirms the gene regulatory capabilities of miRNAs. A recent

11

study found that “miRNA transfer can fine-tune gene expression during generation of the
immune response and increase the complexity of communication between immune cells” (Chen,
Liang et al. 2012).

Cell communication is a key factor which can manipulate the cell

environment and produce analogous cell responses that can alter gene expression and lead to the
activation or repression of corresponding molecular pathways. miRNAs can also have hormone
like affects in terms of reaching and manipulating close and far away neighbors which further
promotes the capability of miRNAs to regulate genes. Thus, the lack of cell-to-cell
communication can lead to diseased states and can promote cancer development. Most often
miRNAs are studied by observing the expression levels of miRNAs in altered states. This
approach can pose difficulties due to the genetic diversity of tumors and constant mutations that
arise from cancer (Chen, Liang et al. 2012). Since miRNAs can mediate the cell-to-cell
communication further studies should focus on targeting the altered cellular mechanisms to be
help discover biomarkers and develop therapeutics.
miRNAs not only a critical factor in cell communication but they also take part in cell
growth and reproduction. Shifts in cell cycle checkpoints can lead to alterations in cell cycle
progression, cell differentiation, and programmed cell death. Diseased states can lead to overexpression or under-expression of miRNAs. Downregulation of miRNAs can result from
genomic loss, alterations of genomic histone acetylation, variations in methylation, and
repression of oncogenic and/or tumor suppressor transcription factors (Jansson and Lund 2012).
Upregulation of miRNAs can result from loss of epigenetic markers (Jansson and Lund 2012).
Upregulated miRNAs are functionally classified as oncogenes while downregulated miRNAs are
functionally classified as tumor suppressors (Jansson and Lund 2012). For instance, in non-small
cell lung cancer miRNA-17 and miRNA-200b are upregulated while miRNA-181 is
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downregulated (Nadal, Truini et al. 2015) (Markou 2015). Hence, miRNA-17 and miRNA-200b
act as oncogenes while miRNA-181 acts as a tumor suppressor.
1.2.1c. Examples of miRNAs in NSCLC
miRNAs from tissue and blood samples are signature factors for diagnosis, prognosis,
and therapy. There are many examples of miRNAs that are associated with NSCLC. Novel
biomarkers of NSCLC including downregulated miRNAs have been cited such as: miR-520h,
miR-34b, and miR-448. Novel biomarkers of NSCLC including upregulated miRNAs have also
been cited such as: miR-22 and miR-654-3p. According to Xu et al. (2015), miR-34b and miR520h take part in the coordination of NSCLC, miR-22 is an oncogene biomarker, and miR-6543p prohibits NSCLC progression while miR-448 promotes NSCLC progression. More
upregulated miRNAs present in NSCLC include: miR-141, miR-193b, miR-200b, miR-301, let7g, miR-331, miR-331, miR-758, miR-744, miR-106a, miR-19a, miR-17, miR-19b, miR-93,
miR-20b, miR-106b, miR-215, miR-25, miR-200c, and miR-24. According to Nadal et al.
(2015), miR-141, miR-200b, miR-193b, and miR-301 all of which were upregulated in NSCLC
and were distinguished as novel serum biological markers for lung malignancy detection.
miRNAs are also prognostic markers for lung cancer. High-expression of miR-155, miR21, miR-106a, miR-93 and low-expression of let-7a-2, let-7b, miR-145 are associated with
unfavorable outcomes of adenocarcinoma patients (Shen & Jiang, 2012). Low levels of miR-1
and miR-499 and high levels of miR-486 and miR-30d are associated with unfavorable
prognosis. miR-145 is a predictive biomarker for lung adenocarcinoma. miR-200b, miR-30c-1,
miR-510, miR-630, miR-657 predict lung cancer recurrence. miR-221 and miR-222 are related
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to aggressive NSCLC while miR-374a is associated with poor patient survival in early-stage
NSCLC (Shen & Jiang, 2012).
There are experimentally targeted miRNAs that regulate many pathways responsible for
repression of E- cadherin, cytoskeleton rearrangement, and focal adhesion and stress fibers all
leading to the spread of lung cancer (Figure 8) (L. Jiang & Qiu, 2013). Involved pathways
include JAK/STAT, MAPK pathway, Wnt signaling pathway, and Notch Signaling pathway.
miRNAs that are known to regulate invasion and metastasis in lung cancer (Figure 9) (L. Jiang &
Qiu, 2013). miR-125a-5p, miR-21, and miR-378 lead to the spread of lung cancer to the brain,
liver, and bone (L. Jiang & Qiu, 2013). miR-126, miR-30a, miR-206, miR-200, miR-200c, and
miR125a-3p suppress the spread of lung cancer (L. Jiang & Qiu, 2013). The invasive lung cancer
phenotype may be addressed by the regulation of the following miRNAs: miR-125b, miR-210,
miR-103, miR-194, and miR-500 (L. Jiang & Qiu, 2013).
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Figure 8. Experimentally validated miRNAs and their target pathways involved in invasion
and metastasis.
The micro RNAs (miRNAs) target many pathways responsible for repression of E- cadherin,
cytoskeleton rearrangement, and focal adhesion and stress fibers all leading invasion and
metastasis of lung cancer. Involved pathways include JAK/STAT, MAPK pathway, Wnt signaling
pathway, and Notch Signaling pathway (L. Jiang & Qiu, 2013). Figure was reproduced with
permission from reference 23; see appendix. EMT: Epithelial- Mesenchymal Transition PI3K:
Phosphoionositide-3-Kinase, EGF: Epidermal Growth Factor, IGF: Insulin-like Growth Factor,
TGF: Transforming Growth Factor, ECM: Extracellular Matrix, RTK: Receptor Tyrosine
Kinase
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Figure 9. miRNAs known to regulate invasion and metastasis in lung cancer.
miR-125a-5p, miR-21, and miR-378 lead to the invasion and metastasis of lung cancer to the
brain, liver, and bone. miR-126, miR-30a, miR-206, miR-200, miR-200c, and miR125a-3p inhibit
the invasion and metastasis of lung cancer. The invasive lung cancer phenotype may be
addressed by the regulation of the following miRNAs: miR-125b, miR-210, miR-103, miR-194,
and miR-500 (L. Jiang & Qiu, 2013). Figure was reproduced with permission from reference 23;
see appendix.
1.2.2. lncRNAs
The study of lncRNAs in the molecular biology field is relatively new. lncRNAs have
become more important in understanding the biology of cancer and the paradigm of gene
regulation. lncRNAs are functional RNA molecules that bypass translation and regulate gene
function. lncRNAs are composed of 200 base pairs or greater and were discovered using histone
modifications; lncRNAs are a class of non-coding RNAs (ncRNAs) which were once thought to
be “junk” in human genome. Many lncRNAs have been identified but only a few have been
functionally annotated. More studies on lncRNAs are being carried out to define lncRNA
regulatory pathways. It has also been studied that lncRNA expression differs between tissues
types and disease conditions. For example, lncRNA expression differ between normal tissue and
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NSCLC tissue; lncRNA expression also differs between adenocarcinoma and squamous cell
carcinoma which are subtypes of NSCLC. This regulatory factor is promising for cancer
diagnosis and prognosis and introduces RNA-based therapy (J. Yang et al., 2014).
1.2.2a. lncRNA categorization based on target location
lncRNAs can be categorized into two categories based on the location of the genomic
target: cis and trans acting lncRNAs. If the genomic target is located close to the site of synthesis
and regulates nearby genes, this is known as cis-acting lncRNAs. On the other hand, trans-acting
lncRNA has a genomic target located far from the site of synthesis and acts to regulate gene
expressions that are farther away, on different chromosomes, or on homologous chromosomes
(Vance & Ponting, 2014).
1.2.2b. lncRNA categorization based on transcription site
lncRNAs can be differentiated according to the location of transcription. lncRNAs can be
transcribed from different regions: intronic, intergenic, sense, antisense, and bidirectional regions
(Figure 10). lncRNAs transcribed from the introns of coding genes are called intronic lncRNAs
also known as lintronic RNAs (J. Chen, Wang, Zhang, & Chen, 2014). lncRNAs induced from in
between two coding genes are called intergenic lncRNAs (J. Chen, Wang, Zhang, & Chen,
2014). Sense lncRNAs are transcripts from the same sequence as the coding gene and lncRNAs
from the opposite gene coding sequence are called antisense lncRNAs (J. Chen, Wang, Zhang, &
Chen, 2014). Bidirectional lncRNAs or divergent lncRNAs are transcripts that begin at the start
of another coding gene (Zhao & Lin, 2015).
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Figure 10. lncRNAs transcribed from different regions.
Long non-coding RNAs (lncRNAs) can be transcribed from in between two coding genes, from
introns of coding genes, from the same gene coding sequence, from the opposite gene coding
sequence, from the beginning of another coding gene known as intergenic lncRNA, intronic
lncRNA, sense lncRNA, antisense lncRNA, and divergent lncRNA respectively (Zhao & Lin,
2015). Figure was reproduced with permission from reference 58; see appendix.
1.2.2b. lncRNA Functions
lncRNAs play a role in chromatin regulation, transcription regulation, and posttranscriptional regulation; they also play an important role in tumorigenesis. lncRNAs functions
range from a molecular level to a cellular level. lncRNAs serve many functions such as a
transcriptional activator, a transcriptional repressor, a transcriptional guide, and a scaffold for
chromatin modification complex. In addition to transcriptional and epigenetic control, lncRNAs
are involved in post-transcriptional regulation, like miRNAs. Studies reveal interactions between
miRNAs and lncRNAs suggesting a role play in cancer diagnosis and prognosis (G. Yang et al.,
2014). Much like miRNAs, lncRNAs were thought to be information deficient. Like miRNAs,
lncRNAs regulate transcription and therefore regulate gene expression but the impact of gene
regulation by lncRNAs is not yet understood. The similarities between these regulatory factors
can be important in understanding disease progression and developing cancer therapies.
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lncRNAs can also act as decoys and signals. A lncRNA that functions as a decoy binds to the
protein and removes them from chromatin. A lncRNA that functions as a scaffold allows for
subunits to assemble and work together. A lncRNA that functions as a guide binds to the protein
and targets the gene to regulate gene expression. A lncRNA that function as signals send signals
to distinguish gene expression (J. Chen, Wang, Zhang, & Chen, 2014). Furthermore, lncRNAs
can act as flexible scaffold for chromatin- modifying complexes, enhancer RNAs, tumor
suppressing signalers, RNA processors, RNA-RNA inter-actors, and miRNA sequesters. For
example, MEG3 is noted as a tumor suppressor as it is downregulated in cancer cell lines and
when overexposed prevents proliferation of the cancer cells in hepatocellular carcinoma
(Prensner & Chinnaiyan, 2011). Further understanding of how lncRNAs function is important in
understanding molecular disease progression thus leading to advanced mechanistic targeting of
the disease.
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Figure 11. lncRNAs have various functions.
Long non-coding RNAs (lncRNAs) could act as decoys, scaffolds, guides, or signals. A lncRNA
that functions as a decoy binds to the protein and removes them from chromatin. A lncRNA that
functions as a scaffold allows for subunits to assemble and work together. A lncRNA that
functions as a guide binds to the protein and targets the gene to regulate gene expression. A
lncRNA that function as signals send signals to distinguish gene expression (J. Chen, Wang,
Zhang, & Chen, 2014). Figure was reproduced with permission from reference 8; see appendix.
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1.2.2c. Examples of lncRNAs in NSCLC
Much like miRNAs, lncRNAs have also been found in cancer. MALAT1, H19, GAS5,
PVT1, and HOTAIR are among the few lncRNAs found in lung cancer. Like miRNAs, lncRNAs
have been associated with oncogenic and tumor suppressor activities. H19 is highly expressed in
lung carcinomas, upregulated by Myc and hypoxic conditions, and functions as an oncogene in
tumorigenesis. MALAT1 is also an oncogene and is highly expressed in lung cancers. H19
function as oncogenes while GAS5 acts a tumor suppressor. BANCR is a known lncRNA and is
under-expressed in NSCLC in tumor tissues and takes part in melanoma cell migration (G. Yang
et al., 2014). Many other lncRNAs have been found such as CAR10, RGMBAS1, GHSROS,
NKX2-AS1, BCYRN1, DLX6-AS1, SOX2-OT, CARLo-5, Lnc_bc060912, MVIH, HNF1AAS1, CCAT2, LUADT1, ZXF1, ANRIL, SCALI, NRG1, GAS6-AS1, LOC788228, DQ786227,
PANDAR, MEG3, SPRY4-IT1, and AK126698. Many of these lncRNAs function to promote
cell proliferation, migration, and metastasis. Some of these lncRNAs function to induce
apoptosis and suppress cell proliferation (Wei & Zhou, 2016).
There are known lncRNAs in NSCLC that are correlated to specific functions. CCAT2,
HOTAIR, BANCR, AK126698, MALAT1, GAS6-AS1, and MEG3 are NSCLC-associated
lncRNAs (Figure 12). CCAT2 and AK126698 are involved in pathways that result in invasion
and metastasis. AK12669 may also be applied as a potential target for reversing NSCLC
cisplatin resistance (J. Chen, Wang, Zhang, & Chen, 2014). MALAT1, GAS6-AS1, and MEG3
are involved in different pathways that lead to invasion and metastasis. MALAT1 acts as a
potential diagnostic and prognostic marker for NSCLC. MEG3 not only acts a tumor suppressor
but acts as potential therapeutic target for NSCLC. HOTAIR is involved in pathway leading to
apoptosis and G0/G1 cell cycle regulations. HOTAIR also act as a potential chemotherapy target.
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BANCR is involved in pathways leading to epithelial mesenchymal transition (EMT) (J. Chen,
Wang, Zhang, & Chen, 2014).

Figure 12. Known lncRNAs in NSCLC and their functions.
CCAT2, HOTAIR, BANCR, AK126698, MALAT1, GAS6-AS1, and MEG3 are NSCLC-associated
lncRNAs. CCAT2 and AK126698 are involved in pathways that result in invasion and metastasis.
MALAT1, GAS6-AS1, and MEG3 are involved in different pathways that lead to invasion and
metastasis. HOTAIR is involved in pathway leading to apoptosis and G0/G1 cell cycle
regulations. BANCR is involved in pathways leading to epithelial mesenchymal transition (J.
Chen, Wang, Zhang, & Chen, 2014). Figure was reproduced with permission from reference 8;
see appendix.

1.3. Microarray Analysis
In biology, genes are studied in many different ways including experimental and
computational approaches. In this study, a microarray was used for gene expression analysis. A
microarray is a 2D chip that harbors thousands of bound DNA sequences to its surface. Target
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DNA sequences hybridize to the surface that is also probed with complementary DNA
sequences. There are three types of microarray: spotted arrays on glass, self-assembled arrays,
and in situ synthesized arrays (Bumgarner, 2013). Microarrays are assembled in a way to allow
for gene expression analysis. First, RNA is extracted from isolated cells of interest and enriched
for mRNA. The enriched mRNA is reverse transcribed into cDNA and the samples are
fluorescently labeled. These labeled samples hybridize to the microarray plate and the plate is
scanned to measure hybridization and in turn gene expression. Microarrays are not only used for
gene expression analysis but they are also used for transcription factor binding analysis, and
genotyping; they have been widely used to study single nucleotide polymorphisms. Given the
vast array of functions a microarray contributes to, microarrays comprise of some limitations.
Microarrays are not a direct measurement of DNA or RNA at high or low concentration, hence
the signal is not linearly proportional. Microarrays can only detect nucleic acid sequences that
are probed on the microarray plate therefore not contributing to the discovery of novel genes.
Microarrays remain advantageous in allowing for gene regulation analysis (Bumgarner, 2013).
Microarray analysis of NSCLC can lead to the understanding of regulatory pathways.
Many regulatory pathways are involved in NSCLC including the STAT3 signaling pathway,
Hedgehog signaling pathway, Ras pathway, and TGF-B pathway (Brambilla & Gazdar, 2009).
These regulatory pathways function in cell proliferation, invasion, angiogenesis, metastasis, and
resistance to apoptosis (Brambilla & Gazdar, 2009). Therefore, studying the genes involved in
these pathways as well as the regulatory factors of these genes like miRNAs and lncRNAs is
important for targeting tumor pathogenesis and honing therapeutic strategies.
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CHAPTER 2: Hypothesis and Objectives

Hypothesis:
Variable gene expression was observed due to the different sample characteristics of NSCLC.
NSCLC in this study is further examined according to regulatory factors. Molecular factors such
as lncRNAs and miRNAs are fundamental in the interplay of gene regulation in order to ensure
cellular homeostasis.
In this study, it is hypothesized that: miRNAs, lncRNAs, and differentially expressed genes in
NSCLC may have a biological relationship which further recommends molecular target
experiments.
Objective 1:
To identify biologically and statistically significant differentially expressed genes in non-small
cell lung cancer patient samples and non-small cell lung cancer patient samples with normal
lungs
Objective 2:
To identify miRNAs and lncRNAs that target the aforementioned identified differentially
expressed genes
Objective 3:
To propose regulatory networks that include the found miRNAs and lncRNAs that target the
differentially expressed genes
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CHAPTER 3: Materials and Methods
3.1. Dataset
The dataset selection criteria included sample size, sample type, recent studies, and
median centered values. The dataset chosen corresponds to the molecular pathology article
authored by Kadara et al., 2013, from the Journal of the National Cancer Institute (JNCI) titled
“Transcriptomic Architecture of the Adjacent Airway Field Cancerization in Non-Small Cell
Lung Cancer” . The dataset selected contains 226 total samples consisting of NSCLC tumor lung
tissue samples, NSCLC normal lung tissue samples, and NSCLC airway samples. Two groups
from the chosen dataset were obtained: NSCLC tumor lung tissue samples vs. NSCLC normal
lung tissue samples.
3.2. Software
The microarray samples were obtained from the Gene Expression Omnibus (GEO)
dataset database and the gene expression profiles were downloaded. GEO is a user-friendly
database allowing users to search for datasets in published sources as well as allowing users to
access and download the corresponding data. Once the dataset was downloaded, RStudio was
used to process the microarray data samples, an open source used for statistical computations and
graphics; it is a front-end interface allowing for easy data input, analysis, and visualization. Once
the differentially expressed genes were manually paired with miRNAs and lncRNAs, each list
was filtered, and uploaded into Cytoscape v3.4.0. Cytoscape is also an open source used for
network visualization. The differentially expressed genes’ list was uploaded into Database for
Annotation, Visualization and Integrated Discovery (DAVID 6.8) for functional annotation.
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3.3. Databases
GeneCards was used to perform functional annotation of the differentially expressed
genes as well as to find the miRNAs that target the respective gene. miRTarBase is an
experimentally verified miRNA target interaction database. miRTarBase was used to pair
miRNAs that target the differentially expressed genes. NONCODE is a database that annotates
lncRNAs. NONCODE was used to manually pair the differentially expressed genes with
lncRNAs. starBase v2.0 is a lncRNA database used to make miRNA-lncRNA target interactions.
starBase v2.0 was used to create miRNA-lncRNA target interactions. Target Explorer powered
by Ingenuity is an online database used to convey biological content through providing
interaction networks and biological pathways and relationships. Target Explorer was used to
suggest relationships between miRNAs, lncRNAs, and differentially expressed genes.
Table 1. Table of open source databases used in this study.
This table contains a list of open source databases used in this study as well as their respective
references.
Database

Reference

Gene Expression Omnibus

https://www.ncbi.nlm.nih.gov/geo/

GeneCards

http://www.genecards.org/

miRTarBase

http://mirtarbase.mbc.nctu.edu.tw/

NONCODE2016

http://noncode.org/index.php

starBase v2.0

http://starbase.sysu.edu.cn/

Target Explorer-Ingenuity

https://targetexplorer.ingenuity.com/index.htm

DAVID 6.8

https://david.ncifcrf.gov/

.
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Figure 13. Schematic overview of online databases used in this study.
This overview shows the open source and validated online databases used in this computational
study.
3.4. Samples
Samples were retrieved and downloaded from GEO using the following accession
number: GSE44077. This dataset included 226 total samples comprising a 986.1 Mb file. This
dataset included 110 NSCLC samples and 116 NSCLC airway samples. Of the 226 samples, 110
NSCLC samples were chosen for this study. Selection criteria for the samples was based on the
location profile of the sample; different location profiles of this dataset included matched
NSCLC tumors and airway epithelia with varying distances from the tumor. In this study, only
matched NSCLC tumors were studied. The raw expression data were in .CEL format. Further
processing was done for the downloaded samples. The samples were corrected and normalized
using Robust Multi-Array Average (RMA) and transformed using log base 2 in order to reveal
the values of the expression data to allow for further analysis of the differentially expressed
genes.
3.5. Sample Characteristics
This study contained matched samples from NSCLC patients. The two groups studied
include: 55 samples from NSCLC patients and 55 samples from NSCLC patients with normal

27

lungs. NSCLC patients may have adjacent lung tissue to the tumor that appears normal at an
early diagnosis stage or the adjacent normal lung tissue may not have been effected by radiation
or other treatments (American Cancer Society). The remaining samples from the dataset include:
lung cancer patients’ samples and airway samples which are irrelevant to this study.
3.6. Sample Processing
The samples were processed using R version 3.3.2. The data was uploaded in .txt format
and named DATA. Csv. This file contains all the samples including the NSCLC samples (n=55)
and NSCLC with normal lungs’ (n=55) samples.

The NSCLC samples correspond to

GSM1077844,GSM1077846,GSM1077848,GSM1077853,GSM1077855,GSM1077857,GSM10
77864,GSM1077866,GSM1077868,GSM1077873,GSM1077875,GSM1077877,GSM1077892,G
SM1077895,GSM1077896,GSM1077902,GSM1077904,GSM1077906,GSM1077911,GSM1077
913,GSM1077915,GSM1077922,GSM1077924,GSM1077926,GSM1077933,GSM1077935,GS
M1077937,GSM1077944,GSM1077946,GSM1077948,GSM1077952,GSM1077954,GSM10779
56,GSM1077963,GSM1077965,GSM1077967,GSM1077973,GSM1077981,GSM1077984,GSM
1077985,GSM1077991,GSM1077993,GSM1077995,GSM1078001,GSM1078003,GSM107800
5,GSM1078010,GSM1078016,GSM1078018,GSM1078020,GSM1078027,GSM1078029,GSM1
078031,GSM1078061,GSM1078063. The NSCLC with normal lungs’ samples correspond to
GSM1077845,GSM1077847,GSM1077849,GSM1077854,GSM1077856,GSM1077858,GSM10
77865,GSM1077867,GSM1077869,GSM1077874,GSM1077876,GSM1077878,GSM1077893,G
SM1077894,GSM1077903,GSM1077905,GSM1077907,GSM1077912,GSM1077914,GSM1077
916,GSM1077923,GSM1077925,GSM1077927,GSM1077934,GSM1077936,GSM1077938,GS
M1077945,GSM1077947,GSM1077949,GSM1077953,GSM1077955,GSM1077957,GSM10779
64,GSM1077966,GSM1077968,GSM1077974,GSM1077975,GSM1077976,GSM1077982,GSM
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1077983,GSM1077986,GSM1077992,GSM1077994,GSM1077996,GSM1078002,GSM107800
4,GSM1078006,GSM1078011,GSM1078012,GSM1078017,GSM1078019,GSM1078021,GSM1
078028,GSM1078030,GSM1078032. This data was saved for further processing.
3.7. Sample Processing: Differential Expression of Genes
A log2 histogram was created to visualize the distribution of the expression value means
of the samples. The values on the extremes of the plot represent the differentially expressed
genes. A box plot was created to determine if the NSCLC samples and the normal samples are
comparable. Box plots are used to compare different variables of a group of data samples in
order to show a trend among the dataset. This means that a boxplot shows distribution values for
selected samples for a dataset; a box plot specifically shows if the values selected are median
centered. A centered configuration of the median line indicates samples are fit for comparison.
A cluster dendogram was created to group the samples according to similar characteristics.
Cluster dendograms group samples based on correlation coefficients of the expression values.
This illustrates the samples in nodes and branches. A scatter plot was created to visualize the
relationship between the two groups of samples: NSCLC patients and NSCLC patients with
normal lungs. Points that lay farther from the red line represent the differentially expressed
genes. Biological and statistical significance were defined using a fold cut-off value = 2 and a pvalue = 0.01, respectively. A volcano plot was produced to present the biological (fold cut-off
value) and statistical significance (p-value) in one graph. The fold cut-off correlates to the
difference between the means of the conditions, the differences between the differentiated genes
and the undifferentiated genes. The larger the fold cut-off the more significant the data. The pvalue correlates to the likelihood of finding significance by chance. In other words, defining a
low p-value means that the significance is not by chance. A heatmap was also produced to
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visualize the level of expression of the hierarchically clustered differentially expressed genes; red
represents the over-expressed genes and blue represents the under-expressed genes.
The differentially expressed genes were manually inputted into GeneCards to perform
functional annotation. The differentially expressed genes were also manually paired with
miRNAs using miRTarBase. The miRNAs were filtered using literature associated with NSCLC
as well as choosing miRNAs that have a strong evidence validation method (i.e. reporter assay,
western blot, and qPCR). The differentially expressed genes were also manually paired with
lncRNAs using NONCODE. The lncRNAs were filtered using literature associated with
NSCLC.
3.8. Systems Approach
Filtered miRNAs and their matched differentially expressed genes were organized into a
table and uploaded into Cytoscape version 3.4.0. The table was created into a text file and used
to link the filtered miRNAs to the differentially expressed genes to create a gene regulatory
network. A network was created to visualize the manually paired miRNAs with their respective
differentially expressed genes.
lncRNA associated with NSCLC were paired with the filtered miRNAs using starBase
v2.0, organized into a table, and uploaded into Cytoscape. The table was also created into a text
file used to link the filtered miRNAs to already NSCLC-associated lncRNAs to create a
regulatory network. Another regulatory network was created to connect the filtered miRNAs and
the differentially expressed genes from this dataset to the NSCLC-associated lncRNAs. Another
table was created that included the filtered miRNAs, their associated differentially expressed
genes, and their associated NSCLC-associated lncRNAs, converted into a text file, and uploaded
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into Cytoscape. This network was created to visualize connections between the filtered miRNAs,
NSCLC-associated lncRNAs, and differentially expressed genes.
All of the differentially expressed genes were uploaded with the official gene symbol into
DAVID 6.8 in a list format and were functionally annotated. DAVID clustered the genes based
on similarly related genes into functionally related groups. This was used for further
interpretation.
Target Explorer was used to provide more comprehensive results. Selected differentially
expressed gene symbols, miRNAs, and lncRNAs were entered into this online biomedical toolkit
to determine biological relationships. These biological relationships were used to suggest
regulatory relationships between miRNAs, lncRNAs, and differentially expressed genes. It
helped confirm regulatory targets and suggest other biological functions. This will also help
suggest further molecular target experiments.

Figure 14. Schematic overview of study design.
This study design shows the steps taken to create regulatory networks that connect differentially
expressed genes, miRNAs, and NSCLC-associated lncRNAs in NSCLC.
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CHAPTER 4: Results
4.1. Data Validation and Quality Check for Samples in this Study
The 110 NSCLC samples in this study were obtained from GEO with the following
accession number GSE44077 (Figure 15). A log2 histogram, box plot, and cluster dendogram
were created for sample analysis and quality assurance of results. In addition, a scatter plot,
volcano plot, and heatmap were created in order to allow for further analysis. Differentially
expressed genes were identified and used to create gene regulatory networks to their respective
miRNAs and lncRNAs.

Figure 15. Flowchart of samples chosen from GEO (GSE44077).
A total of 226 samples were acquired from GSE44077. 55 NSCLC patient samples and 55
NSCLC patients with normal lung tissue samples were chosen for this study and further
analyzed. The remaining samples from the dataset include: lung cancer patients’ samples and
airway samples which are irrelevant to this study.
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4.1.1. Testing for Data Distribution of Samples
Expression data from different data sets were collected. The data were first pre-processed
to allow for appropriate comparison. First, the expression values were log-2 transformed then the
distribution of the log-2 transformed data was examined. The log2 transformed histogram of the
data was produced to check the behavior of the data and to visualize the distribution of the
expression value means. The advantage of taking the log2 allows the user to compare the
expression value means and take the ratio between the means. The distribution of the expression
values in the log2 histogram is not evenly distributed nor symmetric (Figure 16). The log2
transformation of this dataset skews the bell curve formation of the histogram to the left. The left
tail of the histogram suggests differentially expressed genes that are under-expressed and the
right tail of the histogram suggest differentially expressed genes that are over-expressed. In this
study, most of the differentially expressed genes appear to be over-expressed. This was later
confirmed with the volcano plot (Figure 20).
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Figure 16. Log2 histogram of the NSCLC and normal lung tissue samples.
The distribution of the expression values is not evenly distributed nor is it symmetric. The
histogram is bell-shaped curved and skewed to the left. The left tail of the histogram suggests
differentially expressed genes that are under-expressed and the right tail of the histogram
suggest differentially expressed gene that are over-expressed in NSCLC and normal lung tissue
samples. This Figure was produced by RStudio using DATA.csv.
4.1.2. Testing for Data Uniformity of Samples
All the green box plots represent the normal lung tissue samples from this dataset and all
the red box plots represent the NSCLC samples from this dataset. This box plot shows an almost
even distribution of values which suggests that these samples are fit for comparison (Figure 17).
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Figure 17. Box plot of the NSCLC and normal lung tissue samples.
The green box plots represent the normal lung tissue samples from the GSE44077 dataset and all
the red box plots represent the NSCLC samples from this dataset. An almost even distribution of
median values is observed among the samples deeming the samples fit for comparison. This
Figure was produced by RStudio using DATA.csv.

4.1.3. Classifying Samples by Cluster Analysis
The hierarchical clustering shows that the characteristically related samples were grouped
together. All the NSCLC and normal lung tissue samples were grouped together except for three
NSCLC samples; these three NSCLC samples were also grouped together (Figure 18). There
were two major clusters present: NSCLC and NSCLC normal lung samples. A third cluster was
also present that represented three NSCLC samples; this remote cluster may be a result of a
misdiagnosis or mislabeling.
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Figure 18. Cluster Dendogram of the NSCLC and normal lung tissue samples.
All the NSCLC and normal lung tissue samples were grouped together except for three NSCLC
samples; these three NSCLC samples were also grouped together. All characteristically similar
samples were grouped together. This Figure was produced by RStudio using DATA.csv.
4.2. Identification of Biologically and Statistically Significant Differentially Expressed
Genes
4.2.1. Genomic Expression Levels Between NSCLC and Normal Lung Samples
The scatter plot produced shows the relationship between two variables (Figure 19). The
relationship between the NSCLC samples and the NSCLC normal lung samples is roughly linear
(Figure 19). The majority of the data samples have similar genomic correlations which is
indicated by the overlap of data points. Each gene has a specific expression value denoted by an
individual data point. Data points closer to the line indicate similar gene expression. Data points
above the line are over-expressed and data points below the line are under-expressed. The
outliers on the scatter plot, lie further from the line and indicate variable expression differences
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in the data. In this study these data points represented the differentially expressed genes and the
differentially expressed genes were further analyzed.

Figure 19. Scatter Plot showing gene expression between NSCLC patients and NSCLC
patients with normal lungs.
Scatter plot of the NSCLC cancerous lung samples and the NSCLC normal lung samples was
illustrated by RStudio using DATA.csv. The relationship is roughly linear. Overlap of data points
indicate similar gene expression. Data points above the line are over-expressed and data points
below the line are under-expressed.
4.2.2. Determining Biologically and Statistically Significant Differentially Expressed
Genes
A common approach in bioinformatics analysis of microarray is to combine statistical
analysis with negative-log expression ratios. A typical visualization tool for this two-dimensional
analysis is the volcano plot (Figure 20). The volcano plot measures the fold cut-off, biological
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significance, on the x-axis and the p-value, statistical significance, on the y-axis. The more
statistically significant data appear higher in the graph and the upregulated data and the
downregulated data appear to the left and right side of the graph, respectively. More specifically,
data points to the right of the red line and above the green line represent statistically and
biologically significant upregulated differentially expressed genes. Data points to the left of the
blue line and above the green line represent statistically and biologically downregulated
differentially expressed genes. Applying such analysis to our dataset resulted in 108
differentially expressed genes, of which 105 are known genes of biological and statistical
significance in this dataset; two genes lack significant found similarities and one gene is of
unknown function. Most of the differentially expressed genes in this study are upregulated
(Figure 20). Figure 20 also reiterates the findings in Figure 16.
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Figure 20. Volcano Plot demonstrating the relationship between NSCLC patients and NSCLC
patients with normal lungs.
The volcano plot shows a relationship between the biological (fold cut-off =2) and statistical (pvalue=0.01) significance in one graph. Genes below the horizontal green line are considered not
significant. Genes to the right of red line are upregulated and genes to the left of the blue line
are downregulated. Genes of interest lie in the upper right sector and the upper left sector. 108
differentially expressed genes were identified and most of these genes are upregulated. This
Figure was illustrated by RStudio using DATA.csv.

4.2.3. Visualizing Expression Patterns of Differentially Expressed Genes
Hierarchical clustering of the differentially expressed genes (n=108) resulted into 2
clusters and the samples (n=110) into 3 clusters as previously determined from Figure 18 (Figure
21). This heat map showed expression values of the differentially expressed genes in the
different NSCLC sample type. The over-expressed genes are depicted in red and the underexpressed genes are depicted in blue. The identified differentially expressed genes that are overexpressed in cancer samples are under-expressed in normal samples.
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Figure 21. Heatmap exhibiting expression pattern of identified differentially expressed genes.
The heatmap hierarchically clusters the differentially expressed genes (n=108) and the samples
(n=110). Red represents the over-expressed genes and blue represents the under-expressed
genes. The differentially expressed genes are labeled on the y-axis and divided into 2 clusters
and the samples are labeled on the x-axis and divided into 3 clusters. Samples are outlined in
columns and the differentially expressed genes are depicted in rows. This Figure was illustrated
by RStudio using DATA.csv.
4.2.4. Functional Annotation of Differentially Expressed Genes of Biological and
Statistical Significance
There were a total of 33,252 genes in this dataset, but only 108 differentially expressed
genes of biological and statistical significance were identified (Table 2). They were further
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analyzed using online databases to create regulatory networks to connect miRNAs, NSCLCassociated lncRNAs, and differentially expressed genes.
Table 2. Table of differentially expressed genes identified.
The 108 differentially expressed genes (DEGs) are listed and annotated with their respective
Affymetrix gene ID and their respective official gene symbol. There are 105 known differentially
expressed genes, 2 genes that lack significant hits., 1 unknown gene.
AFFYMETRIX_ID
8055323

Name

Gene_Symbol

NCK associated protein 5

8099524

LIM domain binding 2

7917649

Transforming growth factor beta receptor 3

8095886

C-X-C motif chemokine ligand 13

8056518

Sodium voltage-gated channel alpha subunit 7

8133876

CD36 molecule

8145047

Surfactant protein C

8094301

Slit guidance ligand 2

7932407

ST8 alpha-N-acetyl-neuraminide alpha-2,8sialyltransferase 6

7971444

Carboxypeptidase B2

7972157

Endothelin receptor type B

8064904

Fermitin family member 1

7932254

Integrin subunit alpha 8

8091385

Ceruloplasmin

8082928

Claudin 18

7907271

Flavin containing monooxygenase 2

NCKAP5
LDB2
TGFBR3
CXCL13
SCN7A
CD36
SFTPC
SLIT2
ST8SIA6
CPB2
EDNRB
FERMT1
ITGA8
CP
CLDN18
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FMO2

8156571

Chromosome 9 open reading frame 3

8044225

Sulfotransferase family 1C member 4

7979307

DLG associated protein 5

8113666

Semaphorin 6A

8122176

Transcription factor 21

8147891

Polycystic kidney and hepatic disease 1
autosomal recessive-like 1

7985741

ATP/GTP binding protein like 1

7934898

Ankyrin repeat domain 22

8103789

Glycoprotein M6A

8127502

Long intergenic non-protein coding RNA 472

8058591

Acyl-CoA dehydrogenase, long chain

7933855

Rhotekin 2

8013341

Microfibrillar associated protein 4

7944164

Transmembrane protease, serine 4

8044021

Interleukin 1 receptor like 1

8013989

Solute carrier family 6 member 4

8029693

FosB proto-oncogene, AP-1 transcription factor
subunit

7914075

Ficolin 3

8016841

Transmembrane protein 100

8114964

Serine peptidase inhibitor, Kazal type 1

8082597

Collagen type VI alpha 6 chain

C9orf3
SULT1C4
DLGAP5
SEMA6A
TCF21
PKHD1L1
AGBL1
ANKRD22
GPM6A
LINC00472
ACADL
RTKN2
MFAP4
TMPRSS4
IL1RL1
SLC6A4
FOSB
FCN3
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TMEM100
SPINK1
COL6A6

8126729

Chloride intracellular channel 5

8057797

Serum deprivation response

8179967

Advanced glycosylation end-product specific
receptor

8125341

Advanced glycosylation end-product specific
receptor

8178771

Advanced glycosylation end-product specific
receptor

8017885

ATP binding cassette subfamily A member 8

8096301

Secreted phosphoprotein 1

7901256

Cytochrome P450 family 4 subfamily B
member 1

8141094

Pyruvate dehydrogenase kinase 4

8132318

Anillin actin binding protein

7946033

Hemoglobin subunit beta

8077499

Long intergenic non-protein coding RNA 312

8097628

Hedgehog interacting protein

7940654

Secretoglobin family 1A member 1

7951297

Matrix metallopeptidase 12

7996819

Cadherin 3

8138363

Sclerostin domain containing 1

8029086

Carcinoembryonic antigen related cell adhesion
molecule 5

7996264

Cadherin 5

8144917

Lipoprotein lipase

CLIC5
SDPR
AGER
AGER
AGER
ABCA8
SPP1
CYP4B1
PDK4
ANLN
HBB
LINC00312
HHIP
SCGB1A1
MMP12
CDH3
SOSTDC1
CEACAM5
CDH5
LPL
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7964722

WNT inhibitory factor 1

8132092

INMT-FAM188B readthrough

8116780

Desmoplakin

8067140

Cytochrome P450 family 24 subfamily A
member 1

8171427

PIR-FIGF readthrough

7981732

Immunoglobulin heavy variable 4-31

8145317

ADAM like decysin 1

8117395

Histone cluster 1 H2B family member f

8091537

Immunoglobulin superfamily member 10

7964872

Protein tyrosine phosphatase, receptor type B

8151532

Fatty acid binding protein 4

8079060

Vasoactive intestinal peptide receptor 1

8154692

TEK receptor tyrosine kinase

7983890

Myocardial zonula adherens protein

8007420

Amine oxidase, copper containing 3

8052753

Gastrokine 2

7946323

Olfactory receptor family 5 subfamily P
member 2

8109383

Glutamate ionotropic receptor AMPA type
subunit 1

8135594

Caveolin 1

8098060

Relaxin/insulin like family peptide receptor 1

8122334

Atypical chemokine receptor 4

WIF1
NMD candidate
DSP
CYP24A1
PIR-FIGF
IGHV4-31
ADAMDEC1
HIST1H2BF
IGSF10
PTPRB
FABP4
VIPR1
TEK
MYZAP
AOC3
GKN2
OR5P2
GRIA1
CAV1
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RXFP1
ACKR4

8057578

Calcitonin receptor like receptor

8065412

Cystatin SN

7960464

Von Willebrand factor

7917199

Tubulin tyrosine ligase like 7

8155754

MAM domain containing 2

7946579

Lymphatic vessel endothelial hyaluronan
receptor 1

7951217

Matrix metallopeptidase 7

8121181

Four and a half LIM domains 5

7951271

Matrix metallopeptidase 1

7991762

Hemoglobin subunit alpha 1

7991766

Hemoglobin subunit alpha 1

7919139

Ankyrin repeat domain 20 family member A12,
pseudogene

7919146

Ankyrin repeat domain 20 family member A12,
pseudogene

8014974

Topoisomerase DNA II alpha

7934979

Ankyrin repeat domain 1

8101957

Endomucin

8043468

Immunoglobulin kappa constant

8043436

Immunoglobulin kappa constant

8043449

Immunoglobulin kappa constant

8083494

Membrane metalloendopeptidase

8101881

CALCRL
CST1
VWF
TTLL7
MAMDC2
LYVE1
MMP7
FHL5
MMP1
HBA1
HBA1
ANKRD20A12P
ANKRD20A12P
TOP2A
ANKRD1
EMCN

Alcohol dehydrogenase 1B class 1, beta
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IGKC
IGKC
IGKC
MME
ADH1B

polypeptide
7902565

Adhesion G protein-coupled receptor L2

8170119

Four and a half LIM domains 1

7965110

Noncoding transcript identified by NONCODE

7924069

RNA, U5A small nuclear 8, pseudogene

8043441

Immunoglobulin Kappa Variable 1D-27,
pseudogene

7999384

Noncoding transcript identified by NONCODE

7986637

Immunoglobulin Heavy Variable 1/OR15-1,
nonfunctional

8043470

Immunoglobulin Kappa Variable 3D-11

8173924

Unknown noncoding sequence

ADGRL2
FHL1
NONHSAT029647
RNU5A-8P
IGKV1D-27
NONHSAT140505
IGHV1OR15-1
IGKV3D-11
Unknown

4.3. Systems Approach: Creating Regulatory Networks
4.3.1. Connecting Differentially Expressed Genes and miRNAs via Interaction
Networks
Six hundred eighty-one miRNAs were matched to the differentially expressed genes. The
miRNAs were filtered according to literature and miRTarBase’s strong evidence validation
methods (reporter assay, western blot, and qPCR). The filtration narrowed the original list to 66
miRNAs (Table 3). The regulatory network created in Cytoscape shows many overlapping
connections between the miRNAs and the differentially expressed genes and indicates a manyto-many systemic analysis relationship (Figure 22). This network was constructed on Cytoscape
and exhibits the filtered miRNAs that are known to target these differentially expressed genes.
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DEGs
miRNAs

Figure 22. Regulatory network of miRNAs and differentially expressed genes.
This network shows many overlapping and many-to-many relationships, specifically, it shows the miRNAs that target the differentially
expressed genes (DEGs). Table 3 represents the annotations in this interaction network. Table 3 below was uploaded into Cytoscape
in .csv format and Cytoscape was used to create this network. The colors and sizes of the circles and the lines do not have significant
meaning.
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Table 3. Table of filtered regulatory miRNAs paired with DEGs.
This table annotates 66 of the 681 miRNAs and their respective differentially expressed gene
target from this dataset. These miRNAs were filtered based on literature and miRTarBase’s
strong validation methods (i.e. reporter assay, western blot, qPCR).
miRNA

Gene Symbol

mir-223-5p

HHIP, ADH1B

mir-25-3p

MYZAP

miR-654-3p

CYP24A1

miR-520h

CAV1, SLC6A4

miR-34b

ADH1B, CAV1, ACADL

miR-200b

HHIP

miR-138-5p

LPL, FABP4, EMCN

miR-503-5p

ANLN, TMEM100

miR-503-3p

LYVE1

miR-145-5p

MMP1, MMP12

miR-222-5p

MMP1

miR-367-3p

MYZAP

mir-18a-3p

LPHN2

mir-19a

PTPRB

mir-20a

SLC6A4, CAV1, TMEM100

mir-19b-3p

NCKAP5, LPHN2, PTPRB

miR-21

TGFBR3, TOP2A, TCF21

miR-106a-5p

SCL6A4, TMEM100, CAV1

miR-146a

SPP1

miR-155-5p

HHIP, CD36, LPL

miR-192-5p

CAV1, RTKN2, DLGAP5, FERMT1, CYP24A1, GRIA1, ALNL,
ABCA8

miR-203a-3p

CAV1, MMP1, TOP2A

miR-210a-5p

SCN7A

miR-9-5p

DSP, CDH3

miR-708-5p

TOP2A

miR-375

ANKRD1

miR-126a-3p

TEK, MMP7

miR-126a-5p

MMP7, AOC3, TMEM100
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miR-30d-3p

SULT1C4

miR-30d-5p

SEMA6A

miR-129-5p

EMCN, SEMA6A

miR-128-3p

TGFBR3, CDH5

miR-30b-3p

ACADL, INMT

mir-30b-5p

SEMA6A

miR-30c-5p

SEMA6A

miR-30c-1-3p ACADL, INMT
miR-30c-2-3p INMT, ACADL
miR-520c-3p

DLGAP5, SLC6A4, TMEM100

miR-520e

DLGAP5, SLC6A4, TMEM100

miR-520b

DLGAP5, SLC6A4, TMEM100

miR-520d-3p

DLGAP5, SLC6A4, TMEM100

miR-520a-3p

DLGAP5, SLC6A4, TMEM100

miR-520h

CAV1, SLC6A4

miR-520g-3p

CAV1, SLC6A4

miR-520d-5p

TOP2A

miR-17-5p

TMEM100, GPM6A, CAV1, SLC6A4

miR-200a-5p

HHIP

miR-106b-5p

SLC6A4, TMEM100, GPM6A, CAV1

miR-193-5p

SLC6A4, TMEM100, CAV1

miR-193-3p

SCN7A

miR-20b-5p

SLC6A4, TMEM100, CAV1

miR-224-5p

FOSB

let-7e-5p

DSP, TGFBR3

miR-221-5p

CLIC5

miR-221-3p

LPHN2

let-7a-5p

TGFBR3

miR-27a-3p

SEMA6A, TGFBR3

miR-10b-5p

HHIP, RTKN2

miR-1254

CD36

miR-574-5p

HHIP, TTLL7

miR-24-3p

INMT, TTLL7
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miR-199a-5p

CAV1

miR-660-3p

CAV1, CLIC5

miR-92a-3p

TTLL7, HBB, MYZAP

miR-30a-3p

SULT1C4

miR-30a-5p

SEMA6A

4.3.2. Connecting NSCLC-associated lncRNAs and miRNAs via Interaction
Networks
The NSCLC-associate lncRNAs include: MALAT1, PVT1, HOTAIR, H19, TUG1,
GAS5, and DLX6-AS1. These 7 lncRNAs were chosen from literature (Table 4) (Wei & Zhou,
2016). Most of these NSCLC-associated lncRNAs are oncogenes (Wei & Zhou, 2016).
MALAT1, PVT1, HOTAIR, H19, and DLX6-AS1 are associated with oncogene functions.
GAS5 and TUG1 are associated with tumor suppressor functions. This network shows many
overlapping and many-to-many relationships between the filtered miRNAs and NSCLCassociated lncRNAs (Figure 23).
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lncRNAs

miRNAs

Figure 23. Regulatory network of NSCLC-associated lncRNAs and miRNAs.
This network shows many overlapping and many-to-many relationships specifically it shows the NSCLC- associated long non-coding
RNAs (lncRNAs) that are known to target miRNAs. Table 4 represents the annotations in this interaction network. Table 4 below was
uploaded into Cytoscape in .csv format and Cytoscape was used to create this network. The colors and sizes of the circles and the
lines do not have significant meaning.
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Table 4. Table of miRNA and lncRNA targets.
These seven long non-coding RNAs (lncRNAs) are associated with NSCLC according to
literature (Wei & Zhou, 2016). These already NSCLC associated-lncRNAs were paired with
miRNA targets already found in this dataset using the online starBase database.
lncRNA
associated
with
NSCLC
miRNA

MALAT1

miR-200b, miR-30c-5p, miR-129-5p, miR-708-5p, miR-17-5p, miR-20a-5p, miR-203a,
miR-155-5p, miR-367-3p, miR-145- 5p, miR-146a, miR-30a-5p, miR-25-3p, miR-106b5p, miR-30b-5p, miR-30d-5p, miR-20b-5p, miR-106a-5p, miR-503-5p, miR-224-5p

H19

miR-17-5p, miR-19a, miR-20a, miR-19b-3p, miR-138-5p, miR-193, miR-106b-5p, miR20b-5p, miR-106a-5p

TUG1

miR-9-5p, miR-138-5p, miR-145-5p, miR-221-3p

HOTAIR

miR-17-5p, miR-19a, miR-20a, miR-19-3p, miR-106b-5p, miR-221-3p, miR-20b-5p,
miR-106a-5p

GAS5

miR-128-3p, miR-221-3p

PVT1

miR-17-5p, miR-20a, miR-203a-3p, miR-24-3p, miR-128-3p, miR-106b-5p, miR-20b5p, miR-106a-5p

DLX6-AS1 miR-199a-5p

4.3.3. Connecting Differentially Expressed Genes, miRNAs, and NSCLC-associated
lncRNAs via Interaction Networks
The regulatory network created shows many overlapping interactive connections between
the miRNAs, NSCLC-associated lncRNAs, and differentially expressed genes (Figure 24).
Figure 24, also indicates many-to-many relationship which combines are reiterates findings from
Figure 22 and Figure 23. These many-to-many systemic analysis relationships observed in
Figure 22, Figure 23, and Figure 24 means that these differentially expressed genes, miRNAs,
and lncRNAs are intertwined and may be involved in NSCLC regulation. These overlapping
interactions were further analyzed using Target Explorer.
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lncRNAs

DEGs
miRNAs

Figure 24. Regulatory network of miRNAs, NSCLC-associated lncRNAs, and differentially expressed genes.
The program used to create the network of NSCLC-associated lncRNAs, miRNAs, and differentially expressed genes (DEGs). This
network shows many overlapping and many-to-many relationships. Table 5 represents the annotations in this interaction network.
Table 5 below was uploaded into Cytoscape in .csv format and Cytoscape was used to create this network. The colors and sizes of the
circles and the lines do not have significant meaning.
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Table 5. Table of lncRNA, miRNA, and DEG targets.
This table annotates the 66 miRNAs with their respective identified differentially expressed gene
(DEG) target from this dataset. The 66 miRNAs are also annotated with their respective NSCLCassociated lncRNAs targets.
lncRNA

miRNA

Gene Symbol

no matches found

mir-223-5p

HHIP, ADH1B

MALAT1

mir-25-3p

MYZAP

no matches found

miR-654-3p

CYP24A1

no matches found

miR-520h

CAV1, SLC6A4

no matches found

miR-34b

ADH1B, CAV1, ACADL

MALAT1

miR-200b

HHIP

H19, TUG1

miR-138-5p

LPL, FABP4, EMCN

MALAT1

miR-503-5p

ANLN, TMEM100

no matches found

miR-503-3p

LYVE1

TUG1, MALAT1

miR-145-5p

MMP1, MMP12

no matches found

miR-222-5p

MMP1

MALAT1

miR-367-3p

MYZAP

no matches found

mir-18a-3p

LPHN2

HOTAIR, H19
HOTAIR, H19,
MALAT1, PVT1

mir-19a

PTPRB

mir-20a

SLC6A4, CAV1, TMEM100

H19, HOTAIR

mir-19b-3p

NCKAP5, LPHN2, PTPRB

TUG1
H19, HOTAIR,
MALAT1, PVT1

miR-21

TGFBR3, TOP2A, TCF21

miR-106a-5p

SCL6A4, TMEM100, CAV1

MALAT1

miR-146a

SPP1

MALAT1

miR-155-5p

other lncRNAs found

miR-192-5p

HHIP, CD36, LPL
CAV1, RTKN2, DLGAP5, FERMT1, CYP24A1,
GRIA1, ALNL, ABCA8

MALAT1, PVT1

miR-203a-3p

CAV1, MMP1, TOP2A

LINC00473

miR-210a-5p

SCN7A

TUG1

miR-9-5p

DSP, CDH3

MALAT1

miR-708-5p

TOP2A

no matches found

miR-375

ANKRD1

other lncRNAs found

miR-126a-3p

TEK, MMP7

no matches found

miR-126a-5p

MMP7, AOC3, TMEM100
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no matches found

miR-30d-3p

SULT1C4

MALAT1

miR-30d-5p

SEMA6A

MALAT1

miR-129-5p

EMCN, SEMA6A

GAS5, PVT1

miR-128-3p

TGFBR3, CDH5

no matches found

miR-30b-3p

ACADL, INMT

MALAT1

mir-30b-5p

SEMA6A

MALAT1

miR-30c-5p

SEMA6A

no matches found

miR-30c-1-3p

ACADL, INMT

no matches found

miR-30c-2-3p

INMT, ACADL

MALAT1

miR-520c-3p

DLGAP5, SLC6A4, TMEM100

MALAT1

miR-520e

DLGAP5, SLC6A4, TMEM100

MALAT1

miR-520b

DLGAP5, SLC6A4, TMEM100

MALAT1

miR-520d-3p

DLGAP5, SLC6A4, TMEM100

MALAT1

miR-520a-3p

DLGAP5, SLC6A4, TMEM100

no matches found

miR-520h

CAV1, SLC6A4

no matches found

miR-520g-3p

CAV1, SLC6A4

no matches found
H19, MALAT1,
HOTAIR, PVT1

miR-520d-5p

TOP2A

miR-17-5p

TMEM100, GPM6A, CAV1, SLC6A4

no matches found
H19, HOTAIR,
MALAT1, PVT1

miR-200a-5p

HHIP

miR-106b-5p

SLC6A4, TMEM100, GPM6A, CAV1

no matches found

miR-193-5p

SLC6A4, TMEM100, CAV1

H19
H19, HOTAIR,
MALAT1, PVT1

miR-193-3p

SCN7A

miR-20b-5p

SLC6A4, TMEM100, CAV1

MALAT1

miR-224-5p

FOSB

other lncRNAs found

let-7e-5p

DSP, TGFBR3

no matches found

miR-221-5p

CLIC5

GAS5, HOTAIR, TUG1

miR-221-3p

LPHN2

other lncRNAs found

let-7a-5p

TGFBR3

no matches found

miR-27a-3p

SEMA6A, TGFBR3

other lncRNAs found

miR-10b-5p

HHIP, RTKN2

no matches found

miR-1254

CD36

no matches found

miR-574-5p

HHIP, TTLL7
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PVT1

miR-24-3p

INMT, TTLL7

DLX6-AS1

miR-199a-5p

CAV1

no matches found

miR-660-3p

CAV1, CLIC5

MALAT1

miR-92a-3p

TTLL7, HBB, MYZAP

no matches found

miR-30a-3p

SULT1C4

MALAT1

miR-30a-5p

SEMA6A

4.4. Differentially Expressed Genes: DAVID Functional Annotation
According to DAVID, the differentially expressed genes were functionally annotated.
DAVID functionally annotated the differentially expressed genes into 19 clusters in order of
highest to lowest enrichment scores. This means that DAVID classified the genes into 19 gene
functional groups. The enrichment score ranks the gene clusters in order of biological
significance. The primary cluster has an enrichment score of 9.71 and the genes are related to
signaling and secretion (Figure 25). The highly common annotations of the first gene cluster
includes: signal, glycoprotein, glycosylation site N-linked, signal peptide, and disulfide bond
annotations. The second cluster has an enrichment score of 2.83 and the genes are related to
immune response and immunoglobulins (Figure 25). The highly common annotations of the
second gene cluster includes: immunoglobulin-fold, immunoglobulin-domain, immunoglobulin
subtype, antigen binding, serine-type endopeptidase activity, gamma receptor pathway signaling
pathway involved in phagocytosis, and complement activation classical pathway annotations.
The third cluster has an enrichment score of 2.36 and the genes are related to the cell
membrane (Figure 26). The highly common annotations of the third gene cluster includes:
membrane, transmembrane, transmembrane helix, transmembrane region, integral component of
membrane, cell membrane, topological domain cytoplasmic, plasma membrane, and topological
domain extracellular annotations.
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Figure 25. DAVID Gene Functional Annotation Clustering: Cluster 1 &2 of 19.
DAVID functionally clustered the uploaded list of 108 differentially expressed genes (DEGs) into
19 clusters. The most biologically significant cluster is associated with signaling and secretion
and has an enrichment score of 9.71. The second most biologically significant cluster is
associated with immune response and immunoglobulins and has an enrichment score of 2.83.

Figure 26. DAVID Gene Functioning Annotation Clustering: Cluster 3 of 19.
The third most biologically significant cluster DAVID identified is associated with the cell
membrane and has an enrichment score of 2.36.
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DAVID also allowed for the differentially expressed genes to be categorized. Categories
included cancer, lung disease or lung cancer, lung function, and NSCLC. These categories and
the corresponding associated differentially expressed genes are presented in Table 6. Some of the
differentially expressed genes overlap between the categories.
Table 6. Table of categorized DEGs.
This table presents the categorized differentially expressed genes (DEGs). AGER, LPL,
SCGB1A, CAV1, GKN2, CYP24A1, MMP1, MMP7 and MMP12 are overlapping between the
categories.
Category
Genes
Cancer
CD36, ST8SAI6, WIF1, AGER, ADH1B, ANKRD1, CDH3, CPB2,
CAV1, CYP24A1, CYP4B1, EDNRB, FMO2, FHL5, GKN2, GRIA1,
IL1RL1, LPL, MMP1, MMP12, MMP7, MME, MFAP4, SPP1,
SCGB1A1, SPINK1, SLIT2, SLC6A4, TOP2A, TGFBR3, VWF
Lung Disease or Lung AGER, CAV1, CYP24A1, HHIP, GKN2, LPL, MMP1, MMP12,
Cancer
MMP7, SCGB1A1, SFTPC
Lung Function
CP, MMP1, MMP12
NSCLC
AGER, MMP1, MMP12, MMP7

Figure 27. Schematic overview of study results.
This overview summarizes this study’s results of connecting differentially expressed genes,
miRNAs, and NSCLC-associated lncRNAs in NSCLC.
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CHAPTER 5: Discussion and Conclusion
5.1. Regulatory Networks: Connecting Differentially Expressed Genes, miRNAs, and
NSCLC-associated lncRNAs
TGFBR3, CAV1, and HHIP were further analyzed. All of these differentially expressed
genes were extracted from our samples and are related to cancer or lung cancer. Using miRNAs
from this dataset and NSCLC associated-lncRNAs potential regulatory networks were created to
show an interplay between the regulatory factors and differentially expressed genes.

5.1.1. Regulatory Network: Connecting TGFBR3, GAS5, miR-21, miR-128
TGFBR3 is a differentially expressed gene in this dataset in which miR-21 targets
TGFBR3

(miRTarBase).

miR-128

targets

TGFBR3

but

it

also

targets

GAS5

(miRTarBase)(starBase). According to Wei et al.,, GAS5 is a known lncRNA that is associated
with NSCLC; GAS5 was not found in this dataset when DEGs were manually paired to
lncRNAs. GAS5 is also known to target miR-21(starBase). GAS5 and TGFBR3 function as
tumor suppressors. In cancer conditions, miR-21 is upregulated and miR-128 is downregulated
(Jiang et al., 2010) (Liang et al., 2016). TGFBR3 and GAS5 are also downregulated in cancer
(Jiang et al., 2010; Liang et al., 2016). Thus, it appears that miR-21 suppresses TGFBR3
expression and miR-128 also appears to induce TGFBR3 expression (Figure 28). Hence, miR128 appears to induce GAS5 expression and in turn GAS5 appears to suppress miR-21
expression (Figure 28).
miR-21 and miR-128 are from the filtered miRNAs in this dataset. miR-128 targeting is
supported by next generation sequencing (less strong evidence). According to Hu et al., miR-128
plays a role in NSCLC tumorigenesis, angiogenesis, and lymph-angiogenesis (Hu et al., 2014).
Hu et al. also demonstrates that miR-128 is downregulated in non-small cell lung cancer tissues
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and acts a tumor suppressor. Recent studies also show, miR-128 also targets TGFBR3
confirming that there is crosstalk between miRNAs and TGF-B signaling (Hu et al., 2014).
According to miRTarBase, miR-21 targeting is supported by more strong evidence (reporter
assay, qPCR). Previous studies show that miR-21 targets TGFBR3, a player in a key tumor
suppressor pathway, TGF-B, and that TGFBR3, a membrane proteoglycan, is under-expressed in
NSCLC (Papagiannakopoulos, Shapiro, & Kosik, 2008). TGF-B pathway is known to promote
tumor suppressor effects (Butz, Rácz, Hunyady, & Patócs, 2012). Previous studies have
confirmed with strong evidence (RT-qPCR) that GAS5 represses miR-21 expression but the
study also shows the negative relationship between miR-21 and GAS5 meaning that mir-21 also
suppresses the expression of GAS5. Both miR-21 and GAS5 regulate each other (Zhang et al.,
2013). This double-sided relationship strengthens the fact that miRNAs and lncRNAs regulate
cellular processes. In the case of NSCLC, this study suggests that the under-expression of GAS5
suppresses miR-21 which suppresses expression of TGFBR3 leading to tumor growth and
metastasis. Finger et al. further validates this point by showing that the under-expression of
TGFBR3 leads to increase in cell migration, invasion, and anchorage independent growth of lung
cancer cells (Finger et al., 2008). Furthermore, GAS5 has been determined as a novel biomarker
for the diagnosis of non-small cell lung cancer (Liang et al., 2016). Recently, miR-21 has also
been coined a novel therapeutic target in lung cancer (Markou, 2016). This further proves the
potential of miRNAs and lncRNA to regulate cancer development which emphasizes the
importance of creating these regulatory network relationships. These regulatory network
relationships can lead to novel biomarkers and therapeutic targets for cancer diagnosis and
progression.
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Figure 28. Regulatory Network Interplay Between TGFBR3, miR-21, miR-128, and GAS5.
In cancer, TGFBR3, miR-128, and GAS5 are downregulated while miR-21 is upregulated
NSCLC (Jiang et al., 2010) (Liang et al., 2016). miR-21 and miR-128 target TGFBR3 while
GAS5 targets miR-21 and miR-128 targets GAS5 (Papagiannakopoulos, Shapiro, & Kosik, 2008)
(Hu et al., 2014) (Zhang et al., 2013). Thus, this suggests that miR-128 induces GAS5
expression. It also appears that GAS5 suppresses miR-21 expression and in turn it appears that
miR-21 suppresses TGFBR3 expression. It also appears that miR-128 induces TGFBR3
expression.
5.1.2. Regulatory Network: Connecting HHIP, MALAT1, miR-200b, miR-155-5p
HHIP is a differentially expressed gene in this dataset in which miR-200b targets HHIP.
miR-155-5p targets HHIP but it also targets MALAT1 (miRTarBase)(starBase). According to
Wei et al., MALAT1 is a known lncRNA that is associated with NSCLC; MALAT1 was also not
found in this dataset when DEGs were manually paired to lncRNAs. MALAT1 is also known to
target miR-200b (starBase). MALAT1 functions as and oncogene while HHIP functions as a
tumor suppressor. In cancer conditions, miR-200b and miR-155-5p are upregulated (Zhou et al.,
2013). HHIP is downregulated in lung cancer (Huang et al., 2011). MALAT1 is also upregulated
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in cancer (Wei & Zhou, 2016). Thus, it appears that miR-200b suppresses HHIP expression and
miR-155-5p also appears to suppress HHIP expression (Figure 29). Hence, miR-200b appears to
induce MALAT1 expression and in turn MALAT1 appears to induce miR-155-5p expression
(Figure 29).
MALAT1 functions by regulating gene expression and not by regulating alternative
splicing in turn influencing lung cancer metastasis (Gutschner et al., 2013). In the case of
NSCLC, this study suggests that the over-expression of MALAT1 induces the expression of
miR-200b which suppresses the expression of HHIP leading to lung cancer cell metastasis. HHIP
has been associated with Chronic Obstructive Pulmonary Disease (COPD) but the pathogenesis
of COPD by HHIP remains unclear. Studies suggest that HHIP influences COPD via the
hedgehog signaling pathway, a pathway important for carcinogenesis. Zhou et al., performed
functional annotation analysis of significant gene expression values between COPD and normal
lung tissues; this analysis demonstrated a relationship with extracellular matrix and cell growth
genes (Zhou et al., 2013).
DAVID was used for further analysis of extracellular matrix genes. MMP1, MMP7, and
MMP12 are extracellular matrix genes found in this dataset. According to DAVID, MMP1 is
functionally associated with a rate of decline of lung function in Chronic Obstructive Pulmonary
Disease and is associated with an increased risk for lung cancer. Polymorphisms in MMP1 and
MMP12 are related to smoking-related lung injury (R. Zhang, He, Yang, Lu, & Liu, 2005).
Over-expression of MMP1 is associated with NSCLC and lymphatic metastasis of NSCLC (UN
et al., 2004). MMP1 and MMP7 are over-expressed in lung microenvironment and distinguish
pulmonary fibrosis from lung diseases (Rosas et al., 2008). MMP1 may also be associated with
lung cancer development (Gouyer et al., 2005). MMP1 is upregulated by substance P to promote
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collagen degradation in lung fibroblasts (Ramos et al., 2007). MMP1 and MMP12 play a role in
lung structural changes leading to development of emphysema (Joos et al., 2002). MMP1
promoter is demonstrated to be a direct target of cigarette smoke in lung epithelial cells (Mercer,
Wallace, Brinckerhoff, & D'Armiento, 2009). This reiterates the findings of Zhou et al. and
further proves the relationship of extracellular genes with COPD or development and regulation
of lung cancer.

Figure 29. Regulatory Network Interplay Between HHIP, miR-155-5p, miR-200b, and
MALAT1.
In cancer, miR-155-5p, miR-200b, and MALAT1 are over-expressed and HHIP is underexpressed (Huang et al., 2011) (Wei & Zhou, 2016). miR-200b and miR-155-5p target HHIP
(Zhou et al., 2013). According to starBase, miR-200b targets MALAT1 and MALAT1 targets
miR-155-5p. Thus, this suggests that miR-200b induces MALAT1 expression. In turn it appears
that MALAT1 induces miR-155-5p expression which appears to result in miR-155-5p
suppressing HHIP expression. It also appears that miR-200b suppresses HHIP expression.
5.1.3. Regulatory Network: Connecting CAV1, PVT1, miR-20b-5p, miR-17-5p
CAV1 is a differentially expressed gene in this dataset in which miR-20b-5p targets
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CAV1

(miRTarBase).

miR-17-5p

targets

CAV1

but

it

also

targets

PVT1

(miRTarBase)(starBase). According to Wei et al., PVT1 is a known lncRNA that is associated
with NSCLC; PVT1 was not found in this dataset when DEGs were manually paired to
lncRNAs. PVT1 is also known to target miR-20b-5p (miRTarBase). PVT1 and CAV1 function
as oncogenes (Wei & Zhou, 2016). The tumor suppressor function of CAV1 depends on the
tissue type and the stage of the tumor; CAV1 is known to act as both a tumor suppressor and an
oncogene (Sunaga et al., 2004). In cancer conditions, miR-20b-5p is downregulated and miR-175p is upregulated (Mogilyansky & Rigoutsos, 2013). CAV1 and PVT1 are also upregulated in
NSCLC cancer. Thus, it appears that miR-20b-5p induces CAV1 expression and miR-17-5p also
appears to induce CAV1 expression (Figure 30). Hence, miR-17-5p appears to induce PVT1
expression and in turn PVT1 appears to induce miR-20b-5p expression (Figure 30).
PVT1 has been defined as a biomarker and therapeutic target for NSCLC (Y.-R. Yang et
al., 2014). PVT1, a 1716 nucleotide lncRNA, is a known oncogene and works to promote
NSCLC cell proliferation through large tumor suppressor kinase 2 (LATS2) expression (Wan et
al., 2016). In the case of NSCLC, this study suggests that the over-expression of PVT1
suppresses miR-20b-5p which suppresses CAV1 expression. CAV1, an oncogene, plays a role in
tumor spreading, growth factor signaling, matrix remodeling, cell to cell adhesion, and
angiogenesis. CAV1 is also known to interact with membrane metalloproteases (MMP) like
MMP1, MMP7, and MMP12. MMPs function to control tumor invasion and metastasis by
degrading extracellular matrix proteins. CAV1 remodels the extracellular membrane by
interacting with MMPs leading to cancer cell migration and metastasis (Senetta et al., 2013).
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Figure 30. Regulatory Network Interplay Between CAV1, miR-17-5p, miR-20b-5p, and PVT1.
In NSCLC, CAV1, miR-17-5p, and PVT1 are over-expressed and miR-20b-5p is under-expressed
(Wei & Zhou, 2016) (Mogilyansky & Rigoutsos, 2013). According to miRTarBase, miR-17-5p
and miR-20b-5p target CAV1. PVT1 targets miR-20b-5p and miR-17-5p targets PVT1. Thus, this
suggests that miR-17-5p induces PVT1 expression and in turn it appears that PVT1 suppresses
miR-20b-5p expression which in turn appears to result in miR-20b-5p suppressing CAV1
expression. On the other hand, it also appears that miR-17-5p induces CAV1 expression.
Not only is miR-20b-5p downregulated but so is miR-106a-5p and miR-203a-3p which
are suppressed by PVT1 and in turn suppresses CAV1 expression (Wei & Zhou, 2016). This
suggests that miR-17-5p induces PVT1 expression and in turn PVT1 suppresses miR-20b-5p,
miR-106a-5p, and miR-203a-3p expression which in turn results in the aforementioned miRNAs
suppressing CAV1 expression (Figure 31).
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Figure 31. Regulatory Network Interplay Between CAV1, miR-17-5p, miR-20b-5p, miR-203a3p, miR-106a-5p, and PVT1.
According to miRTarBase, miR-20b-5p, miR-106a-5p, and miR-203a-3p target CAV1. In
NSCLC, not only is miR-20b-5p downregulated but so is miR-106a-5p and miR-203a-3p which
appear to be suppressed by PVT1. In turn, it also appears that miR-106a-5p and miR-203a-3p
suppress CAV1 expression (Shen & Jiang, 2012). This suggests similar biological relationships
as in Figure 30.
In NSCLC, miR-17-5p, miR-106b-5p, and miR-20a-5p target CAV1 (miRTarBase). Not
only is miR-17-5p upregulated but so is miR-106b-5p and miR-20a-5p which induces CAV1
expression (Shen & Jiang, 2012). This suggests that miR-17-5p, miR-106b-5p, miR-20a-5p
induce CAV1 expression but also induce PVT1 expression and in turn PVT1 suppresses miR20b-5p, miR-106a-5p, and miR-203a-3p expression which in turn results in the aforementioned
miRNAs suppressing CAV1 expression (Figure 32).
Experimental validation of these proposed computational interactions will contribute to
the roadmap for lung cancer diagnosis and therapy.
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Figure 32. Regulatory Network Interplay Between CAV1, miR-17-5p, miR-106b-5p, miR-20a5p, miR-20b-5p, and PVT1.
According to miRTarBase, miR-17-5p, miR-106b-5p, and miR-20a-5p target CAV1. In NSCLC,
not only is miR-17-5p upregulated but so is miR-106b-5p and miR-20a-5p which appear to
induce CAV1 expression (Shen & Jiang, 2012). This suggests similar biological relationships as
in Figure 30.
The fold cut-off and p-value are harsh filters and this may present a problem with
extracting the intended samples from this dataset. An unfiltered heatmap may be produced to
validate the number of extracted samples from the volcano plot. Also, the number of samples in
this study may be a limitation. In the future, computational studies patterns can be validated with
other datasets and compared with RNA-sequencing datasets.

5.2. Conclusion
miRNAs and lncRNAs are fundamental molecular factors that regulate gene expression
to ensure cellular homeostasis in NSCLC and in normal lungs. In this study the aim was to
suggest a biological relationship and to further recommend molecular target experiments to
further connect differentially expressed genes, miRNAs, and lncRNAs. It is clear that miRNAs
and lncRNAs play regulatory mechanisms in controlling NSCLC and it is also clear that there
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are a plethora of miRNA and lncRNA interactions that lead to this regulation. It is also clear that
there are connections between differentially expressed genes, miRNAs, and NSCLC-associated
lncRNAs. The suggested regulatory networks in this study reinforce this notion. However, what
is not clear is how the miRNAs, lncRNAs, and differentially expressed genes work together to
regulate cellular homeostasis.
Tumor suppressor genes like TGFBR3 and HHIP show a connection between
extracellular matrix genes which are functionally known and related to carcinogenesis (Finger et
al., 2008 and Zhou et al., 2013). CAV1, an oncogene, displays a relationship between growth
factor signaling and matrix remodeling all leading to tumor growth and cancer cell metastasis
(Senetta et al., 2013). MALAT1, PVT1, and GAS5 are lncRNAs that regulate gene expression
via miRNA targeting. These networks propose mechanisms of actions to further study miRNAs
and lncRNAs suggesting a crosstalk between miRNAs, lncRNAs, and differentially expressed
genes. Because miRNAs and lncRNAs have proven to play important roles in cellular regulation
as well as cancer progression the regulation of these regulatory pathways can lead to novel
approaches in cancer therapy.
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CHAPTER 6: Future Directions
A better knowledge of the regulatory pathway is important for understanding tumor
pathogenesis. In the present study, the aim was to analyze regulatory gene factors in order to
suggest connections between differentially expressed genes, miRNAs, and lncRNAs. These
factors were computationally studied and suggested. Future studies are needed to validate or
revoke these connections with complementary experimental research. Confirming these
suggested relationships will not only provide insight to the pathogenesis of cancer, but will also
hone therapeutic strategies. Future studies should accomplish the following objectives.
Objective 1
Experimentally validate the suggested regulatory networks. Experimentally determine
whether miRNAs and lncRNAs together can influence differentially expressed genes. This will
lead to a confirmed mechanism of action for NSCLC regulation. This can give insight into
manipulating lung cancer progression and novel therapeutic methods.
Objective 2
Identify more lncRNAs associated with NSCLC and determine their respective
functions. This can contribute to clinical usefulness in cancer diagnosis, prognosis, and therapy.
This crucial especially since lncRNAs are potential biomarker for early diagnosis of NSCLC.
Future studies should also expand on lncRNAs, as it is a new field in molecular biology.
lncRNAs are a novel emerging field and require in-depth analysis including experimental
identification and functional annotation of lncRNAs. This can contribute to online lncRNA
databases for future computational analysis and will lead to a better understanding of cancer
pathogenesis and treatment.
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Objective 3
Future studies should also include RNA sequencing data from NSCLC patients to not
only identify the same patterns, but also validate the connections between differentially
expressed genes, miRNAs, and lncRNAs. This will also lead to possible diagnostic targets and
targeted treatment options for NSCLC patients which could lead to halting the progression of the
disease. This will lead to a better mechanistic understanding of lung cancer regulation.

Figure 33. Schematic overview of future directions.
This overview summarizes the future directions for NSCLC diagnosis, prognosis, and therapy.

70

References
1.AmericanCancerSociety. (5/16/2016). Lung Cancer (Non-Small Cell). Retrieved from
http://www.cancer.org/cancer/lungcancer/
2.AmericanLungAssociation. (Nov 3, 2016). Lung Cancer Fact Sheet. Retrieved from

http://www.lung.org/
3.Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. cell,
116(2), 281-297.
4.Brambilla, E., & Gazdar, A. (2009). Pathogenesis of lung cancer signaling pathways: roadmap
for therapies. The European Respiratory Journal: Official Journal of the European Society for
Clinical Respiratory Physiology, 33(6), 1485–1497. http://doi.org/10.1183/09031936.00014009
5.Bumgarner, R. (2013). Overview of DNA microarrays: types, applications, and their future.
Current protocols in molecular biology, 22.21. 21-22.21. 11.
6.Butz, H., Rácz, K., Hunyady, L., & Patócs, A. (2012). Crosstalk between TGF-β signaling and
the microRNA machinery. Trends in pharmacological sciences, 33(7), 382-393.
7.CDC. (Jan 4, 2016). Global Cancer Statistics. Retrieved from
http://www.cdc.gov/cancer/international/statistics.htm
8.Chen, J., Wang, R., Zhang, K., & Chen, L. B. (2014). Long non-coding RNAs in non-small cell
lung cancer as biomarkers and therapeutic targets. Journal of cellular and molecular medicine,
18(12), 2425-2436.
9.Chen, X., Liang, H., Zhang, J., Zen, K., & Zhang, C.-Y. (2012). Secreted microRNAs: a new
form of intercellular communication. Trends in cell biology, 22(3), 125-132.
10.Chou, C.-H., Chang, N.-W., Shrestha, S., Hsu, S.-D., Lin, Y.-L., Lee, W.H., Yang, C.D.,
Hong, H.C., Wei, T.Y., Tu, S.J. and Tsai, T.R. (2016). miRTarBase 2016: updates to the
experimentally validated miRNA-target interactions database. Nucleic acids research, 44(D1),
D239-D247. W.H., Yang, C.D., Hong, H.C., Wei, T.Y., Tu, S.J. and Tsai, T.R
11.Cure. (April 23, 2016). Medical Illustration: Non-Small Cell Lung Cancer. Retrieved from
http://www.curetoday.com/publications/cure/2016/lung-2016/medical-illustration-nonsmall-celllung-cancer
12.Edgar, R., Domrachev, M., & Lash, A. E. (2002). Gene Expression Omnibus: NCBI gene
expression and hybridization array data repository. Nucleic acids research, 30(1), 207-210.
71

13.Finger, E. C., Turley, R. S., Dong, M., How, T., Fields, T. A., & Blobe, G. C. (2008). TβRIII
suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis, 29(3),
528-535.
14.Gouyer, V., Conti, M., Devos, P., Zerimech, F., Copin, M. C., Créme, E., Wurtz, A., Porte, H.
and Huet, G. (2005). Tissue inhibitor of metalloproteinase 1 is an independent predictor of
prognosis in patients with non-small cell lung carcinoma who undergo resection with curative
intent. Cancer, 103(8), 1676-1684.
15.Gurtan, A. M., & Sharp, P. A. (2013). The role of miRNAs in regulating gene expression
networks. Journal of molecular biology, 425(19), 3582-3600.
16.Gutschner, T., Hämmerle, M., Eißmann, M., Hsu, J., Kim, Y., Hung, G., Revenko, A., Arun,
G., Stentrup, M., Groß, M., Zörnig, M. (2013). The noncoding RNA MALAT1 is a critical
regulator of the metastasis phenotype of lung cancer cells. Cancer research, 73(3), 1180-1189.
17.Hu, J., Cheng, Y., Li, Y., Jin, Z., Pan, Y., Liu, G., Fu, S., Zhang, Y., Feng, K. and Feng, Y.
(2014). microRNA-128 plays a critical role in human non-small cell lung cancer tumorigenesis,
angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C.
European journal of cancer, 50(13), 2336-2350.

18. Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009a). Bioinformatics enrichment tools:
paths toward the comprehensive functional analysis of large gene lists. Nucleic acids research,
37(1), 1-13.
19. Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009b). Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nature protocols, 4(1), 4457.
20. Huang, S., Yang, L., An, Y., Ma, X., Zhang, C., Xie, G., Chen, Z.Y., Xie, J. and Zhang, H.
(2011). Expression of hedgehog signaling molecules in lung cancer. Acta histochemica, 113(5),
564-569.

21.Ibrahim, A. S., Khaled, H. M., Mikhail, N. N., Baraka, H., & Kamel, H. (2014). Cancer
incidence in Egypt: results of the national population-based cancer registry program. Journal of
cancer epidemiology, 2014.
22.Jansson, M. D., & Lund, A. H. (2012). MicroRNA and cancer. Molecular oncology, 6(6),
590-610.

72

23.Jiang, L., & Qiu, X. (2013). MicroRNAs in Invasion and Metastasis in Lung Cancer:
INTECH Open Access Publisher.
24.Jiang, X., Liu, R., Lei, Z., You, J., Zhou, Q., & Zhang, H. (2010). [Defective expression of
TGFBR3 gene and its molecular mechanisms in non-small cell lung cancer cell lines]. Chinese
journal of lung cancer, 13(5), 451-457.
25.Joos, L., He, J.-Q., Shepherdson, M. B., Connett, J. E., Anthonisen, N. R., Paré, P. D., &
Sandford, A. J. (2002). The role of matrix metalloproteinase polymorphisms in the rate of
decline in lung function. Human molecular genetics, 11(5), 569-576.
26.Kadara, H., Fujimoto, J., Yoo, S.-Y., Maki, Y., Gower, A. C., Kabbout, M., Garcia, M.M.,
Chow, C.W., Chu, Z., Mendoza, G. and Shen, L. (2014). Transcriptomic architecture of the
adjacent airway field cancerization in non–small cell lung cancer. Journal of the National
Cancer Institute, 106(3).
27.Lancet, D., Safran, M., Olender, T., Dalah, I., Iny-Stein, T., Inger, A., Harel, A. and Stelzer,
G. (2008, April). GeneCards tools for combinatorial annotation and dissemination of human
genome information. Paper presented at the GIACS Conf. Data Complex Syst.
28.Li, J.-H., Liu, S., Zhou, H., Qu, L.-H., & Yang, J.-H. (2013). starBase v2. 0: decoding
miRNA-ceRNA, miRNA-ncRNA and protein–RNA interaction networks from large-scale CLIPSeq data. Nucleic acids research, gkt1248.
29.Liang, W., Lv, T., Shi, X., Liu, H., Zhu, Q., Zeng, J., Yang, W., Yin, J. and Song, Y. (2016).
Circulating long noncoding RNA GAS5 is a novel biomarker for the diagnosis of non-small cell
lung cancer. Medicine, 95(37), e4608.
30.LillyOncology. Squamous NSCLC. Retrieved from
http://www.lillyoncology.com/education/squamous-nsclc.html
31.MacFarlane, L.-A., & R Murphy, P. (2010). MicroRNA: biogenesis, function and role in
cancer. Current genomics, 11(7), 537-561.
32.Markou, A. (2015). MicroRNA signatures as clinical biomarkers in lung cancer.
33.Markou, A. (2016). miRNA-21 as a novel therapeutic target in lung cancer.

73

34.Mercer, B. A., Wallace, A. M., Brinckerhoff, C. E., & D'Armiento, J. M. (2009).
Identification of a cigarette smoke–responsive region in the distal MMP-1 promoter. American
journal of respiratory cell and molecular biology, 40(1), 4-12.
35.Mogilyansky, E., & Rigoutsos, I. (2013). The miR-17/92 cluster: a comprehensive update on
its genomics, genetics, functions and increasingly important and numerous roles in health and
disease. Cell Death & Differentiation, 20(12), 1603-1614.
36.Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008). Non-small cell
lung cancer: epidemiology, risk factors, treatment, and survivorship. Paper presented at the Mayo
Clinic Proceedings.
37.Nadal, E., Truini, A., Nakata, A., Lin, J., Reddy, R. M., Chang, A. C., Ramnath, N., Gotoh,
N., Beer, D.G. and Chen, G. (2015). A novel serum 4-microRNA signature for lung cancer
detection. Scientific reports, 5.
38.National Cancer Institute. (n.d.). Retrieved January 10, 2017, from http://www.cancer.gov/
39.Papagiannakopoulos, T., Shapiro, A., & Kosik, K. S. (2008). MicroRNA-21 targets a network
of key tumor-suppressive pathways in glioblastoma cells. Cancer research, 68(19), 8164-8172.
40.Prensner, J. R., & Chinnaiyan, A. M. (2011). The emergence of lncRNAs in cancer biology.
Cancer discovery, 1(5), 391-407.
41.Ramos, C., Montaño, M., Cisneros, J., Sommer, B., Delgado, J., & Gonzalez-Avila, G.
(2007). Substance P up-regulates matrix metalloproteinase-1 and down-regulates collagen in
human lung fibroblast. Experimental lung research, 33(3-4), 151-167.
42.Rothschild, S. I. (2013). "Epigenetic therapy in lung cancer–role of microRNAs." Frontiers in
oncology 3: 158.
43.Rosas, I. O., Richards, T. J., Konishi, K., Zhang, Y., Gibson, K., Lokshin, A. E., Lindell,
K.O., Cisneros, J., MacDonald, S.D., Pardo, A and Sciurba, F. (2008). MMP1 and MMP7 as
potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med, 5(4), e93.
44.Senetta, R., Stella, G., Pozzi, E., Sturli, N., Massi, D., & Cassoni, P. (2013). Caveolin-1 as a
promoter of tumor spreading: when, how, where and why. Journal of cellular and molecular
medicine, 17(3), 325-336.

74

45.Shen, J., & Jiang, F. (2012). Applications of microRNAs in the diagnosis and prognosis of
lung cancer. Expert opinion on medical diagnostics, 6(3), 197-207.
46.Sunaga, N., Miyajima, K., Suzuki, M., Sato, M., White, M. A., Ramirez, R. D., Shay, J.W.,
Gazdar, A.F. and Minna, J. D. (2004). Different roles for caveolin-1 in the development of nonsmall cell lung cancer versus small cell lung cancer. Cancer research, 64(12), 4277-4285.
47.UN, T.-S., Chiou, S.-H., Wang, L.-S., Huang, H.-H., CHIANG, S., Shih, A. Y., Chen, Y.,
Chen, C.Y., Hsu, N.Y. and Ming-Chihchou, S.J. (2004). Expression spectra of matrix
metalloproteinases in metastatic non-small cell lung cancer. Oncology reports, 12, 717-723.
48.Vance, K. W., & Ponting, C. P. (2014). Transcriptional regulatory functions of nuclear long
noncoding RNAs. Trends in Genetics, 30(8), 348-355.
49.Wan, L., Sun, M., Liu, G.-J., Wei, C.-C., Zhang, E.-B., Kong, R., Xu, T.P., Huang, M.D. and
Wang, Z.-X. (2016). Long Noncoding RNA PVT1 Promotes Non–Small Cell Lung Cancer Cell
Proliferation through Epigenetically Regulating LATS2 Expression. Molecular cancer
therapeutics, 15(5), 1082-1094.
50.Wei, M.-M., & Zhou, G.-B. (2016). Long Non-coding RNAs and Their Roles in Non-smallcell Lung Cancer. Genomics, Proteomics & Bioinformatics, 14(5), 280-288.
51.Xu, C., Zheng, Y., Lian, D., Ye, S., Yang, J., & Zeng, Z. (2015). Analysis of microRNA
expression profile identifies novel biomarkers for non-small cell lung cancer. Tumori Journal,
101(1), 104-110.
52.Yang, G., Lu, X., & Yuan, L. (2014). LncRNA: a link between RNA and cancer. Biochimica
et Biophysica Acta (BBA)-Gene Regulatory Mechanisms, 1839(11), 1097-1109.
53.Yang, J., Lin, J., Liu, T., Chen, T., Pan, S., Huang, W., & Li, S. (2014). Analysis of lncRNA
expression profiles in non-small cell lung cancers (NSCLC) and their clinical subtypes. Lung
Cancer, 85(2), 110-115.
54.Yang, J.-H., Li, J.-H., Shao, P., Zhou, H., Chen, Y.-Q., & Qu, L.-H. (2011). starBase: a
database for exploring microRNA–mRNA interaction maps from Argonaute CLIP-Seq and
Degradome-Seq data. Nucleic acids research, 39(suppl 1), D202-D209.
55.Yang, Y.-R., Zang, S.-Z., Zhong, C.-L., Li, Y.-X., Zhao, S.-S., & Feng, X.-J. (2014).
Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung
cancer. Int J Clin Exp Pathol, 7(10), 6929-6935.

75

56.Zhang, R., He, Q., Yang, R., Lu, B., & Liu, Y. (2005). [Study on matrix metalloproteinase 1,
9, 12 polymorphisms and susceptibility to chronic obstructive pulmonary disease among Han
nationality in northern China]. Chinese Journal of Epidemiology, 907-910.
57.Zhang, Z., Zhu, Z., Watabe, K., Zhang, X., Bai, C., Xu, M., Wu, F. and Mo, Y.Y. (2013).
Negative regulation of lncRNA GAS5 by miR-21. Cell Death & Differentiation, 20(11), 15581568.
58.Zhao, X.-Y., & Lin, J. D. (2015). Long noncoding RNAs: a new regulatory code in metabolic
control. Trends in Biochemical Sciences, 40(10), 586-596.
59.Zhao, Y., Li, H., Fang, S., Kang, Y., Hao, Y., Li, Z., Bu, D., Sun, N., Zhang, M.Q. and Chen,
R. (2015). NONCODE 2016: an informative and valuable data source of long non-coding RNAs.
Nucleic Acids Research.
60.Zhou, X., Qiu, W., Sathirapongsasuti, J. F., Cho, M. H., Mancini, J. D., Lao, T., Thibault,
D.M., Litonjua, A.A., Bakke, P.S., Gulsvik, A. and Lomas, D.A. (2013). Gene expression
analysis uncovers novel hedgehog interacting protein (HHIP) effects in human bronchial
epithelial cells. Genomics, 101(5), 263-272.

76

APPENDIX
Permission to use Figures in Thesis

Figure A1. Permission to use Figure 1

77

Figure A2. International Agency for Research on Cancer (IARC) grants permission to use
Figure 2 and Figure 3 “as is” for research purposes.

78

Figure A3. Permission to use Figure 4 and Figure 5

79

Figure A4. Permission to use Figure 6

80

Figure A5. Permission to use Figure 7

81

Figure A6. Permission to use Figure 8 and Figure 9

82

Figure A7. Permission to use Figure 10

83

Figure A8. Permission to use Figure 11 and Figure 12

84

